Emergency Access to Insulin Act of 2019

H.R. 938, Bringing Low-cost Options and Competition while Keeping Incentives for New Generics (BLOCKING) Act of 2019, regarding all bio-pharmaceutical related provisions. H.R. 985, Fair Access for Safe and Timely (FAST) Generics Act of 2019, regarding all bio-pharmaceutical related provisions. H.R. 986, Protecting American with Preexisting Conditions Act of 2019, regarding all bio-pharmaceutical related provisions. H.R. 987, Marketing and Outreach Restoration to Empower Health Education Act of 2019, regarding all bio-pharmaceutical related provisions. H.R. 1010, Short-Term, Limited Duration Insurance (STLDI), regarding all bio-pharmaceutical related provisions. H.R. 1323, Rural Hospital Frontier Fairness Act, regarding all bio-pharmaceutical related provisions. H.R. 1385, State Allowance for a Variety of Exchanges (SAVE) Act, regarding all bio-pharmaceutical related provisions. H.R. 1386, Expanded Navigators Resources for Outreach, Learning, and Longevity (ENROLL) Act, regarding all bio-pharmaceutical related provisions. H.R. 1409, Transparency in All Health Care Pricing Act, regarding all bio-pharmaceutical related provisions. H.R. 1425, State Health Care Premium Reduction Act, regarding all bio-pharmaceutical related provisions. H.R. 1478, Insulin importation, regarding all bio-pharmaceutical related provisions. H.R. 1503, Orange Book Transparency Act, regarding all bio-pharmaceutical related provisions. H.R. 1506, Fair and Immediate Release (FAIR) of Generics Act, regarding all bio-pharmaceutical related provisions. H.R. 1520, Purple Book Continuity Act, regarding all bio-pharmaceutical related provisions. H.R. 2011, Protecting Access to Biosimilars Act of 2019, regarding all bio-pharmaceutical related provisions. H.R. 2038, State-based , Market-Oriented, Prescription Drug Negotiations Act of 2019, regarding all bio-pharmaceutical related provisions. H.R. 2064, Product Sample reporting, regarding all bio-pharmaceutical related provisions. S. 61, Safe and Affordable Drugs from Canada Act, regarding all bio-pharmaceutical related provisions. S. 97, Affordable and Safe Drug Importation Act, regarding all bio-pharmaceutical related provisions. S. 102, Prescription Drug Price Relief Act, regarding all bio-pharmaceutical related provisions. S. 344/H.R. 990, Hatch-Waxman Integrity Act, regarding all bio-pharmaceutical related provisions. S. 366/H.R. 1188, FLAT Prices Act- Reduced exclusivity period for certain price hikes, regarding all bio-pharmaceutical related provisions. S. 418, FDA Accountability for Public Safety Act, regarding all bio-pharmaceutical related provisions. S. 419, Protecting Americans from Dangerous Opioids Act, regarding all bio-pharmaceutical related provisions. S. 637, CURE High Drug Prices Act, regarding all bio-pharmaceutical related provisions. S. 657, Drug Price Transparency Act, regarding all bio-pharmaceutical related provisions. S. 658, Accelerated Drug Approval for Prescription Therapies Act, regarding all bio-pharmaceutical related provisions. S. 659, Biologic Patent Transparency Act, regarding all bio-pharmaceutical related provisions. S. 660, Transparency in Petitions Act, regarding all bio-pharmaceutical related provisions. S. 709, Establishes public dashboard for price and utilization of drugs purchased by federal programs, regarding all bio-pharmaceutical related provisions. S. 741 /H.R. 1730, Cancer Drug Parity Act, regarding all bio-pharmaceutical related provisions. S. 844, Short Competition Act, regarding all bio-pharmaceutical related provisions. S. 977, Transparent Drug Pricing Act of 2019, regarding all bio-pharmaceutical related provisions. S. 989, STEER Act, regarding all bio-pharmaceutical related provisions. S. 1140, A bill to amend the Public Health Service Act with respect to the treatment under section 351(k)(7) of such Act (relating to exclusivity for reference products) of certain products deemed to have a biological product license pursuant to section 7002 of the Biologics Price Competition and Innovation Act of 2009, regarding all bio-pharmaceutical related provisions. S.1169, FDA citizen petition, regarding all bio-pharmaceutical related provisions. S. 1209, A bill to amend the Federal Food, Drug, and Cosmetic Act with respect to approval of abbreviated new drug applications, regarding all bio-pharmaceutical related provisions. H.R. 2115, Public Disclosure of Drug Discounts Act, regarding all bio-pharmaceutical related provisions H.R.2296/S.1391, FAIR Drug Pricing Act, regarding all bio-pharmaceutical related provisions H.R.2700, Lowering Prescription Drug Costs and Extending Community Health Centers and other Health Priorities Act, regarding all bio-pharmaceutical related provisions H.R. 3223, Pharmacy Benefit Manager Accountability Study Act, regarding all bio-pharmaceutical related provisions S. 1361/H.R.2584, Preventive Health Savings Act, regarding all bio-pharmaceutical related provisions S. 1437, DTC Act, regarding all bio-pharmaceutical related provisions S.1532, Pharmacy Benefit Managers Accountability Study Act, regarding all bio-pharmaceutical related provisions S.1636, Ensuring Innovation Act, regarding all bio-pharmaceutical related provisions S. 1664, Prescription Drug Price Reporting Act, regarding all bio-pharmaceutical related provisions S. 1801, Affordable Medications Act, regarding all bio-pharmaceutical related provisions S. 1895, Lowering Health Costs Act, regarding all bio-pharmaceutical related provisions S. 1897, a bill to establish a process for updating the labeling of certain drugs with outdated labeling, regarding all bio-pharmaceutical related provisions S. 1897/H.R. 3523, End Price Gouging for Medications Act, regarding all bio-pharmaceutical related provisions S. 2004, Emergency Access to Insulin Act, regarding all bio-pharmaceutical related provisions H.R. 2279/S. 2546, Safe Step Act of 2019, regarding all bio-pharmaceutical related provisions H.R 748/S. 3548, Coronavirus Aid, Relief and Economic Security Act (CARES Act), regarding all bio-pharmaceutical provisions. H.R. 1425, State Health Care Premium Reduction Act, regarding all bio-pharmaceutical related provisions H.R. 6800, Health and Economic Recovery Omnibus Emergency Solutions (HEROES) Act, regarding all bio-pharmaceutical related provisions

Client expense: $1,090,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), SENATE, U.S. Trade Representative (USTR)

S. 1895 - Lower Health Care Costs Act H.R. 2668 - Special Diabetes Program Reauthorization Act of 2019 H.R. 2680 - Special Diabetes Program for Indians Reauthorization Act of 2019 S. 3937 - Special Diabetes Program for Indians Reauthorization Act of 2020 H.R. 2328 - Reauthorizing and Extending Americas Community Health Act (REACH Act) S. 2543 - The Prescription Drug Pricing Reduction Act of 2019 S. 2199, H.R. 4906 - Insulin Price Reduction Act S. 2004, H.R. 4010 -- Emergency Access to Insulin Act of 2019 H.R. 3 - Lower Drug Costs Now Act of 2019 H.R. 5749 - Affordable Insulin for All Act S. 2855, H.R. 5691 - Insulin Affordability Data Collection Act H.R. 19, S. 3129 - Lower Costs, More Cures Act of 2019 Issues and legislation related to drug pricing, specifically as it relates to insulin. Issues and legislation related to a passthrough of any/all savings to beneficiaries using insulin in Medicare Part D. Issues and legislation related to providing flexibility in the split of a deductible between devices and prescription drugs. Issues related to the importance of preserving health insurance protections for individuals with pre-existing conditions. H.R. 5254 - Diabetic Vision Loss and Blindness Prevention Act of 2019 Issues related to providing (during the COVID-19 emergency period) and preserving (after the COVID-19 emergency period) telehealth/telemedicine flexibilities for individuals with type 1 diabetes. S. 4315/H.R. 6666 - COVID-19 Testing, Reaching, And Contacting Everyone Act (TRACE) Act

Client expense: $70,000 · Firm income: Not reported

H.R. 938, Bringing Low-cost Options and Competition while Keeping Incentives for New Generics (BLOCKING) Act of 2019, regarding all bio-pharmaceutical related provisions. H.R. 985, Fair Access for Safe and Timely (FAST) Generics Act of 2019, regarding all bio-pharmaceutical related provisions. H.R. 986, Protecting American with Preexisting Conditions Act of 2019, regarding all bio-pharmaceutical related provisions. H.R. 987, Marketing and Outreach Restoration to Empower Health Education Act of 2019, regarding all bio-pharmaceutical related provisions. H.R. 1010, Short-Term, Limited Duration Insurance (STLDI), regarding all bio-pharmaceutical related provisions. H.R. 1323, Rural Hospital Frontier Fairness Act, regarding all bio-pharmaceutical related provisions. H.R. 1385, State Allowance for a Variety of Exchanges (SAVE) Act, regarding all bio-pharmaceutical related provisions. H.R. 1386, Expanded Navigators Resources for Outreach, Learning, and Longevity (ENROLL) Act, regarding all bio-pharmaceutical related provisions. H.R. 1409, Transparency in All Health Care Pricing Act, regarding all bio-pharmaceutical related provisions. H.R. 1425, State Health Care Premium Reduction Act, regarding all bio-pharmaceutical related provisions. H.R. 1478, Insulin importation, regarding all bio-pharmaceutical related provisions. H.R. 1503, Orange Book Transparency Act, regarding all bio-pharmaceutical related provisions. H.R. 1506, Fair and Immediate Release (FAIR) of Generics Act, regarding all bio-pharmaceutical related provisions. H.R. 1520, Purple Book Continuity Act, regarding all bio-pharmaceutical related provisions. H.R. 2011, Protecting Access to Biosimilars Act of 2019, regarding all bio-pharmaceutical related provisions. H.R. 2038, State-based , Market-Oriented, Prescription Drug Negotiations Act of 2019, regarding all bio-pharmaceutical related provisions. H.R. 2064, Product Sample reporting, regarding all bio-pharmaceutical related provisions. S. 61, Safe and Affordable Drugs from Canada Act, regarding all bio-pharmaceutical related provisions. S. 97, Affordable and Safe Drug Importation Act, regarding all bio-pharmaceutical related provisions. S. 102, Prescription Drug Price Relief Act, regarding all bio-pharmaceutical related provisions. S. 344/H.R. 990, Hatch-Waxman Integrity Act, regarding all bio-pharmaceutical related provisions. S. 366/H.R. 1188, FLAT Prices Act- Reduced exclusivity period for certain price hikes, regarding all bio-pharmaceutical related provisions. S. 418, FDA Accountability for Public Safety Act, regarding all bio-pharmaceutical related provisions. S. 419, Protecting Americans from Dangerous Opioids Act, regarding all bio-pharmaceutical related provisions. S. 637, CURE High Drug Prices Act, regarding all bio-pharmaceutical related provisions. S. 657, Drug Price Transparency Act, regarding all bio-pharmaceutical related provisions. S. 658, Accelerated Drug Approval for Prescription Therapies Act, regarding all bio-pharmaceutical related provisions. S. 659, Biologic Patent Transparency Act, regarding all bio-pharmaceutical related provisions. S. 660, Transparency in Petitions Act, regarding all bio-pharmaceutical related provisions. S. 709, Establishes public dashboard for price and utilization of drugs purchased by federal programs, regarding all bio-pharmaceutical related provisions. S. 741 /H.R. 1730, Cancer Drug Parity Act, regarding all bio-pharmaceutical related provisions. S. 844, Short Competition Act, regarding all bio-pharmaceutical related provisions. S. 977, Transparent Drug Pricing Act of 2019, regarding all bio-pharmaceutical related provisions. S. 989, STEER Act, regarding all bio-pharmaceutical related provisions. S. 1140, A bill to amend the Public Health Service Act with respect to the treatment under section 351(k)(7) of such Act (relating to exclusivity for reference products) of certain products deemed to have a biological product license pursuant to section 7002 of the Biologics Price Competition and Innovation Act of 2009, regarding all bio-pharmaceutical related provisions. S.1169, FDA citizen petition, regarding all bio-pharmaceutical related provisions. S. 1209, A bill to amend the Federal Food, Drug, and Cosmetic Act with respect to approval of abbreviated new drug applications, regarding all bio-pharmaceutical related provisions. H.R. 2115, Public Disclosure of Drug Discounts Act, regarding all bio-pharmaceutical related provisions H.R.2296/S.1391, FAIR Drug Pricing Act, regarding all bio-pharmaceutical related provisions H.R.2700, Lowering Prescription Drug Costs and Extending Community Health Centers and other Health Priorities Act, regarding all bio-pharmaceutical related provisions H.R. 3223, Pharmacy Benefit Manager Accountability Study Act, regarding all bio-pharmaceutical related provisions S. 1361/H.R.2584, Preventive Health Savings Act, regarding all bio-pharmaceutical related provisions S. 1437, DTC Act, regarding all bio-pharmaceutical related provisions S.1532, Pharmacy Benefit Managers Accountability Study Act, regarding all bio-pharmaceutical related provisions S.1636, Ensuring Innovation Act, regarding all bio-pharmaceutical related provisions S. 1664, Prescription Drug Price Reporting Act, regarding all bio-pharmaceutical related provisions S. 1801, Affordable Medications Act, regarding all bio-pharmaceutical related provisions S. 1895, Lowering Health Costs Act, regarding all bio-pharmaceutical related provisions S. 1897, a bill to establish a process for updating the labeling of certain drugs with outdated labeling, regarding all bio-pharmaceutical related provisions S. 1897/H.R. 3523, End Price Gouging for Medications Act, regarding all bio-pharmaceutical related provisions S. 2004, Emergency Access to Insulin Act, regarding all bio-pharmaceutical related provisions H.R. 2279/S. 2546, Safe Step Act of 2019, regarding all bio-pharmaceutical related provisions H.R 748/S. 3548, Coronavirus Aid, Relief and Economic Security Act (CARES Act), regarding all bio-pharmaceutical provisions. H.R. 1425, State Health Care Premium Reduction Act, regarding all bio-pharmaceutical related provisions H.R. 6800, Health and Economic Recovery Omnibus Emergency Solutions (HEROES) Act, regarding all bio-pharmaceutical related provisions

S. 1895 - Lower Health Care Costs Act H.R. 2668 - Special Diabetes Program Reauthorization Act of 2019 H.R. 2680 - Special Diabetes Program for Indians Reauthorization Act of 2019 S. 3937 - Special Diabetes Program for Indians Reauthorization Act of 2020 H.R. 2328 - Reauthorizing and Extending Americas Community Health Act (REACH Act) S. 2543 - The Prescription Drug Pricing Reduction Act of 2019 S. 2199, H.R. 4906 - Insulin Price Reduction Act S. 2004, H.R. 4010 -- Emergency Access to Insulin Act of 2019 H.R. 3 - Lower Drug Costs Now Act of 2019 H.R. 5749 - Affordable Insulin for All Act S. 2855, H.R. 5691 - Insulin Affordability Data Collection Act H.R. 19, S. 3129 - Lower Costs, More Cures Act of 2019 Issues and legislation related to drug pricing, specifically as it relates to insulin. Issues and legislation related to a passthrough of any/all savings to beneficiaries using insulin in Medicare Part D. Issues and legislation related to providing flexibility in the split of a deductible between devices and prescription drugs. Issues related to the importance of preserving health insurance protections for individuals with pre-existing conditions. H.R. 5254 - Diabetic Vision Loss and Blindness Prevention Act of 2019 Issues related to providing (during the COVID-19 emergency period) and preserving (after the COVID-19 emergency period) telehealth/telemedicine flexibilities for individuals with type 1 diabetes. Issues related to hospital inpatient blood glucose monitoring.

Client expense: $110,000 · Firm income: Not reported

Affordable Care Act (ACA); ACA Regulations; ACA Stabilization; Health Reform; Risk Adjustment; Opioids; Individual Market Reform; Health Care Costs; Mental Health; CSRs; Transparency; Surprise billing, Transparency, Prior Authorization; All payer claims database; Negotiated rate disclosure; Medicare for All; Maternal health; Senior's health care; Community health; NBPP (Notice Benefit and Payment Parameters), COVID-19 Response/Relief Packages, Healthcare access/privacy; Risk Corridors; COBRA; Telehealth; SEPs; CDC Guidance Testing; Safe Harbor; COVID-19; Postal Reform; Single Employer Pensions; H.R.1384 - 116th Congress (2019-2020) Medicare for All Act of 2019 Sponsor: Rep. Jayapal, Pramila [D-WA-7] (Introduced 02/27/2019) H.R.2003 - 116th Congress (2019-2020) Ensuring FEHBP Coverage During Shutdowns Act Sponsor: Rep. Cummings, Elijah E. [D-MD-7] (Introduced 04/01/2019) H.R.2004 - 116th Congress (2019-2020) Ensuring FEDVIP and FLTCIP Coverage During Shutdowns Act Sponsor: Rep. Cummings, Elijah E. [D-MD-7] (Introduced 04/01/2019) S.973 - 116th Congress (2019-2020) Ensuring FEDVIP and FLTCIP Coverage During Shutdowns Act Sponsor: Sen. Smith, Tina [D-MN] (Introduced 04/01/2019) S.971 - 116th Congress (2019-2020) Ensuring FEHBP Coverage During Shutdowns Act Sponsor: Sen. Smith, Tina [D-MN] (Introduced 04/01/2019) H.R.1520 - 116th Congress (2019-2020) Purple Book Continuity Act of 2019 Sponsor: Rep. Eshoo, Anna G. [D-CA-18] (Introduced 03/05/2019) S.1895 - 116th Congress (2019-2020) Lower Health Care Costs Act Sponsor: Sen. Alexander, Lamar [R-TN] (Introduced 06/19/2019) H.R.1046 - 116th Congress (2019-2020) Medicare Negotiation and Competitive Licensing Act of 2019 Sponsor: Rep. Doggett, Lloyd [D-TX-35] H.R.3630 - 116th Congress (2019-2020) No Surprises Act Sponsor: Rep. Pallone, Frank, Jr. [D-NJ-6] H.R.3439 - 116th Congress (2019-2020) PATIENT Act Sponsor: Rep. Beyer, Donald S., Jr. [D-VA-8] H.R.3107 - 116th Congress (2019-2020) Improving Seniors' Timely Access to Care Act of 2019 Sponsor: Rep. DelBene, Suzan K. [D-WA-1] H.R.2279 - 116th Congress (2019-2020) Safe Step Act Sponsor: Rep. Ruiz, Raul [D-CA-36] S.1895 - 116th Congress (2019-2020) Lower Health Care Costs Act Sponsor: Sen. Alexander, Lamar [R-TN] S. 2546 - 116th Congress (2019-2020) Safe Step Act Sponsor: Sen. Lisa Murkowski (R-AK) S. 2004 - 116th Congress (2019-2020) Ensuring FEDVIP and FLTCIP Coverage During Shutdowns Act Sponsor: Rep. Elijah Cummings (D-MD-07) H.R. 2774 - 116th Congress (2019-2020) Primary Care Patient Protection Act of 2019 Sponsor: Rep. Brad Schneider (D-IL-10) H.R. 5826 - 116th Congress - Second Session Consumer Protections Against Surprise Medical Bills Act of 2020 Sponsor: Rep. Richard Neal(D-MA-01) S. 3548 - 116th Congress - Second Session Coronavirus Aid, Relief, and Economic Security Act Sponsor: Sen. Mitch McConnell (R-KY) H.R. 5551 - 116th Congress - Second Session Ensuring Child Health Coverage Compensation in Divorce Act of 2020 Sponsor: Del. Eleanor Holmes Norton (D-DC At-Large) H.R. 5575 - 116th Congress - Second Session Primary and Behavioral Health Care Access Act of 2020 Sponsor: Rep. Lauren Underwood (D-IL-14) H.R. 5688 - 116th Congress - Second Session Reducing Administrative Costs and Burdens in Health Care Act of 2020 Sponsor: Rep. Cindy Axne (D-IA-03) H.R. 5754 - 116th Congress - Second Session Rural ER Access Act Sponsor: Rep. Mark Green (R-TN-07) H.R. 5763 - 116th Congress - Second Session National Telehealth Strategy and Data Advancement Act Sponsor: Rep. Greg Gianforte (R-MT At-Large) H.R. 5800 - 116th Congress - Second Session Ban Surprise Billing Act Sponsor: Rep. Bobby Scott (D-VA-03) H.R. 5807 - 116th Congress - Second Session Know Your Provider Act of 2020 Sponsor: Rep. John Larson (D-CT-01) H.R. 5916 - 116th Congress - Second Session Transparent Health Care Pricing Act of 2020 Sponsor: Rep. Mike Gallagher (R-WI-08) Public Law 116-127 (H.R. 6201) - 116th Congress - Second Session First Coronavirus Response Act Sponsor: Rep. Nita Lowey (D-NY-17) H.R. 6336 - 116th Congress - Second Session To amend title XI of the Social Security Act to provide for a waiver of payment reductions under the Medicare and Medicaid programs for certain nonapproved capital expenditures undertaken by health care facilities during the COVID-19 emergency. Sponsor: Rep. Dan Bishop (R-NC-09) H.R. 6311 - 116th Congress - Second Session Care for COVID-19 Act Sponsor: Rep. Raul Ruiz (D-CA-36) H.R. 6299 - 116th Congress - Second Session Rapid Coverage of COVID-19 Vaccine Act of 2020 H.R. 5817 - 116th Congress - Second Session Fair and Honest Advance Cost Estimate for Patients Act of 2020 Sponsor: Rep. Devin Nunes (R-CA-22) H.R. 5816 - 116th Congress - Second Session Continuing Care for Patients Act of 2020 Sponsor: Rep. Gwen Moore (D-WI-04) HR. 5809 - 116th Congress - Second Session Better Information Act of 2020 Sponsor: Rep. Don Beyer (D-VA-08) H.R. 5826 -116th Congress - Second Session Consumer Protections Against Surprise Medical Bills Act of 2020 Sponsor: Rep. Richard Neal (D-MA-01) H.R. 5924 - 116th Congress - Second Session To amend the Public Health Service Act to authorize a loan repayment program to encourage specialty medicine physicians to serve in rural communities experiencing a shortage of specialty medicine physicians, and for other purposes. Sponsor: Rep. David McKinley (R-WV-01) H.R. 6004 - 116th Congress - Second Session Transparency and Accountability in Health Care Costs and Prices Act of 2020 Sponsor: Rep. Dan Lipinski (D-IL-03) H.R. 6005 - 116th Congress - Second Session Know the Price Act Sponsor: Rep. Tom Malinowski (D-NJ-07) H.R. 6132 - 116th Congress - Second Session Social Determinants for Moms Act of 2020 Sponsor: Rep. Lucy McBath (D-GA-06) H.R. 6135 - 116th Congress - Second Session No More Narrow Networks Act of 2020 Sponsor: Rep. Jan Schakowsky (D-IL-09) H.R. 6136 - 116th Congress - Second Session Protecting Consumers from Unreasonable Rates Act of 2020 Sponsor: Rep. Jan Schakowsky (D-IL-09) H.R. 6137 - 116th Congress - Second Session Innovative Maternal Payment And Coverage To Save Moms Act Sponsor: Rep. Jan Schakowsky (D-IL-09) H.R. 6138 - 116th Congress - Second Session Tech to Save Moms Act Sponsor: Rep. Eddie Bernice Johnson (D-TX-30) H.R. 6149 - 116th Congress - Second Session Medicaid Report on Expansion of Access to Coverage for Health Act Sponsor: Rep. Joe Cunningham (D-SC-01) H.R. 6151 - 116th Congress - Second Session CARING for Kids Act Sponsor: Rep. Abby Finkenauer (D-IA-01) H.R. 6173 - 116th Congress - Second Session Covering Coronavirus Test Act of 2020 Sponsor: Rep. Diana DeGette (D-CO-01) H.R. 6213 - 116th Congress - Second Session No Cost for COVID-19 Testing Act Sponsor: Rep. Frederica Wilson (D-FL-24) H.R. 6222 - 116th Congress - Second Session Ensuring Affordable COVID-19 Preventive Care Act of 2020 Sponsor: Rep. Jan Schakowsky (D-IL-09) H.R. 6232 - 116th Congress - Second Session To require the Secretary of Health and Human Services, through the National Disaster Medical System, to provide for certain laboratory reimbursement for diagnostic testing for COVID-19 in uninsured individuals. Sponsor: Rep. Tony Cardenas (D-CA-29) H.R. 6231 - 116th Congress - Second Session Ensuring Access to COVID-19 Preventive Care Act of 2020 Sponsor: Rep. Larry Bucshon (R-IN-08) H.R. 6244 - 116th Congress - Second Session To amend titles XVIII and XIX to provide for coverage at no cost sharing of COVID-19 testing under the Medicaid program and Children's Health Insurance Program. Sponsor: Rep. Robin Kelly (D-IL-02) H.R. 6263 - 116th Congress - Second Session To amend title XVIII of the Social Security Act to waive cost sharing under the Medicare program for certain visits relating to testing for COVID-19. Sponsor: Rep. John Sarbanes (D-MD-03) H.R. 6282 - 116th Congress - Second Session Commission on America's Medical Security Act Sponsor: Rep. Raul Ruiz (D-CA-36) H.R. 6283 - 116th Congress - Second Session Good Samaritan Health Professionals Act of 2020 Sponsor: Rep. Raul Ruiz (D-CA-36) H.R. 1379 - 116th Congress - First Session Ensuring Lasting Smiles Act Rep. Collin Peterson (D-MN-07) H.R. 6810 - 116th Congress - Second Session Health Care Protection Act Sponsor: Rep. Rodney Davis (R-IL-13) H.R. 6808 - 116th Congress - Second Session Health Force and Resilience Force Act of 2020 Sponsor: Rep. Jason Crow (D-CO-06) S. 3606 - 116th Congress - Second Session Health Force and Resilience Force Act of 2020 Sponsor: Sen. Kirsten Gillibrand (D-NY) H.R. 6130 - 116th Congress - Second Session Improving Awareness of Health Coverage Options Act Sponsor: Rep. Josh Harder (D-CA-10) Public Law 116-123 (H.R.6074) - 116th Congress - Second Session Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020 Sponsor: Rep. Nita Lowey (D-NY-17) H.R. 6379 - 116th Congress - Second Session Take Responsibility for Workers and Families Act Sponsor: Rep. Nita Lowey (D-NY-17) H.R. 6800 - 116th Congress - Second Session HEROES Act Sponsor: Rep. Nita Lowey (D-NY-17) H.R. 6426 - 116th Congress - Second Session To direct the Secretary of Health and Human Services to establish a program under which loans shall be made to certain health care organizations to assist such organizations with anticipated revenue loss or higher operating costs as a result of the COVID-19 emergency, and for other purposes Sponsor: Rep. Max Rose (D-NY-11) H.R. 6455 - 116th Congress - Second Session National Commission Regarding the 2019 Novel Coronavirus (COVID-19) Pandemic Act Sponsor: Rep. Bennie Thompson (D-MS-02) H.R. 6409 - 116th Congress - Second Session Assistance for Businesses and Local Economies Act Sponsor: Rep. Ilhan Omar (D-MN-05) Public Law 116-139 (H.R. 266) - 116th Congress - First Session Vehicle for Covid-19 Small Business, Hospital and Testing Funds Sponsor: Rep. Betty McCollum (D-MN-04) H.R. 5566 - 116th Congress - Second Session Patient Fairness Act of 2020 Sponsor: Rep. Warren Davidson (R-OH-08) H.R. 5596 - 116th Congress - Second Session Personalized Care Act of 2020 Sponsor: Rep. Chip Roy(R-TX-21) H.R. 6338 - 116th Congress - Second Session Pandemic Healthcare Access Act Sponsor: Rep. Ted Budd (R-NC-13) H.R. 5808 - 116th Congress - Second Session Save Rural Communities Act of 2020 Sponsor: Rep. Jodey Arrington (R-TX-19) H.R. 7391 - 116th Congress - Second Session To amend title XVIII of the Social Security Act to remove certain geographic and originating site restrictions on the furnishing of telehealth services under the Medicare program. H.R. 5763 - 116th Congress - Second Session National Telehealth Strategy and Data Advancement Act Sponsor: Rep. Greg Gianforte (R-MT At-Large) H.R. 6487 - 116th Congress - Second Session Advancing Connectivity during the Coronavirus to Ensure Support for Seniors Act Sponsor: Rep. Jan Schakowsky (D-IL-09) H.R. 6514 - 116th Congress - Second Session Worker Health Coverage Protection Act Sponsor: Rep. Bobby Scott (D-VA-03) H.R. 6712 - 116th Congress - Second Session American Healthshare Plans Act of 2020 Sponsor: Rep. John Curtis(R-UT-03) H.R. 6746 - 116th Congress - Second Session To require the Secretary of Labor to establish a program for providing portable benefits to eligible workers, and for other purposes Sponsor: Rep. Suzan DelBene (D-WA-01) H.R. 6833 - 116th Congress - Second Session Utilizing and Supporting Evacuated Peace Corps Volunteers Act Sponsor: Rep. Dean Phillips (D-MN-03) H.R. 6411 - 116th Congress - Second Session Emergency Advance Refill Notification Act of 2020 Sponsor: Rep. Lucy McBath (D-GA-06) H.R. 6511 - 116th Congress - Second Session Ensuring Vaccination and Treatment Affordability Act Sponsor: Rep. Chris Pappas (D-NH-01) H.R. 6518 - 116th Congress - Second Session Stop Health Premium Spikes Act of 2020 H.R. 6561 - 116th Congress - Second Session Improving Social Determinants of Health Act of 2020 Sponsor: Rep. Nanette Barragan (D-CA-44) H.R. 6568 - 116th Congress - Second Session Coverage for COVID-19 Treatment Act of 2020 Sponsor: Rep. Lisa Blunt Rochester (D-DE At-Large) H.R. 6634 - 116th Congress - Second Session Emergency COVID Telehealth Response Act Sponsor: Rep. Cindy Axne (D-IA-03) H.R. 6638 - 116th Congress - Second Session Reducing COVID-19 Disparities by Investing in Public Health Act Cosponsor: Rep. Jahana Hayes (D-CT-05) H.R. 6644 - 116th Congress - Second Session To require group health plans and health insurance issuers offering group or individual health insurance coverage to provide coverage for services furnished via telehealth if such services would be covered if furnished in-person during the COVID-19 emergency. Sponsor: Kim Schrier (D-WA-08) H.R. 6645 - 116th Congress - Second Session To direct the Secretary of Health and Human Services, acting through the Director of the National Institute of Mental Health, to conduct or support research on the mental health consequences of SARS-CoV-2 or COVID-19, and for other purposes. H.R. 6654 - 116th Congress - Second Session Emergency COVID Telehealth Response Act Sponsor: Rep. Cindy Axne (D-IA-03) H.R. 6663 - 116th Congress - Second Session Truth in Healthcare Marketing Act of 2020 Sponsor: Rep. Larry Buschon (R-IN-08) H.R. 6742 - 116th Congress - Second Session Protecting Life in Crisis Act Sponsor: Rep. Mike Conaway (R-TX-11) H.R. 6763 - 116th Congress - Second Session COVID-19 Racial and Ethnic Disparities Task Force Act of 2020 Sponsor: Rep. Robin Kelly (D-IL-02) H.R. 6792 - 116th Congress - Second Session Improving Telehealth for Underserved Communities Act of 2020 Sponsor: Rep. Adrian Smith (R-NE-03) H.R. 6797 - 116th Congress - Second Session Children's Health Insurance Program Pandemic Enhancement and Relief Act Sponsor: Rep. Susan Wild (D-PA-07) H.R. 6866 - 116th Congress - Second Session Public Health Emergency Privacy Act Sponsor: Rep. Anna Eshoo (D-CA-18) H.R. 6906 - 116th Congress - Second Session Health Care Emergency Guarantee Act Sponsor: Pramila Jayapal (D-WA-07) H.R. 6918 - 116th Congress - Second Session Paycheck Recovery Act of 2020 Sponsor: Rep. Pramila Jayapal(D-WA-07) H.R. 6925 - 116th Congress - Second Session Medical Innovation Acceleration Act of 2020 Sponsor: Rep. Andy Biggs (R-AZ-05) H.R. 6926 - 116th Congress - Second Session Meeting IMD Needs with Direction Act Sponsor: Rep. Brendan Boyle (D-PA-02) H.R. 6930 - 116th Congress - Second Session Manufacturing API, Drugs, and Excipients in America Act of 2020 Sponsor: Rep. Buddy Carter (R-GA-01) H.R. 6971 - 116th Congress - Second Session Medical Nutrition Therapy Act of 2020 Sponsor: Rep. Eliot Engel (D-NY-16) H.R. 6999 - 116th Congress - Second Session Coronavirus Mental Health and Addiction Assistance Act of 2020 Sponsor: Rep. Tim Ryan (D-OH-13) H.R. 7017 - 116th Congress - Second Session Right to Test Act Sponsor: Rep. Patrick McHenry (R-NC-10) H.R. 7077 - 116th Congress - Second Session Community Solutions for COVID-19 Act Sponsor: Rep. Robin Kelly (D-IL-02) H.R. 7078 - 116th Congress - Second Session Evaluating Disparities and Outcomes of Telehealth During the COVID-19 Emergency Act of 2020 Sponsor: Rep. Robin Kelly (D-IL-02) H.R. 7123 - 116th Congress - Second Session Katherine's Lung Cancer Early Detection and Survival Act of 2020 Sponsor: Rep. Brendan Boyle (D-PA-02) H.R. 7158 - 116th Congress - Second Session Health Enterprise Zones Act of 2020 Sponsor: Anthony Brown (D-MD-04) H.R. 7168 - 116th Congress - Second Session Creating Capacity for Communities in Need Act Sponsor: Vicente Gonzalez (D-TX-15) H.R. 7187 - 116th Congress - Second Session Helping Ensure Access to Local TeleHealth Act of 2020 Sponsor: Rep Glenn Thompson (R-PA-15) H.R. 7190 - 116th Congress - Second Session Increasing Rural Health Access During the COVID-19 Public Health Emergency Act of 2020 Sponsor: Rep. Xochitl Torres Small (D-NM-02) H.R. 7286 - 116th Congress - Second Session Quit Because of COVID-19 Act Sponsor: Rep. Lisa Blunt Rochester (D-DE-At-Large) H.R. 5958 - 116th Congress - Second Session Official Short Title: Senior Health Planning Account Act Sponsor: Rep. Brian Higgins (D-NY-26) H.R. 6209 - 116th Congress - Second Session Reducing Unnecessary Senior Hospitalizations Act of 2020 Sponsor: Rep. Ann Kuster (D-NH-02) H.R. 6436 - 116th Congress - Second Session Police and Fire Health Care Protection Act of 2020 Sponsor: Rep. Steve Chabot (R-OH-01) H.R. 6545 - 116th Congress - Second Session Health Insurance Marketplace Affordability Act of 2020 Sponsor: Rep. Stephanie Murphy (D-FL-07) H.R. 6698 - 116th Congress - Second Session Quality Care for Nursing Home Residents and Workers During COVID-19 Act of 2020 Sponsor: Rep. Jan Schakowsky (D-IL-09) H.R. 6753 - 116th Congress - Second Session Rural Community Hospital Demonstration Extension Act of 2020 Sponsor: Rep. Abby Finkenauer (D-IA-01) H.R. 6781 - 116th Congress - Second Session Paycheck Protection Program Improved Coordination Act of 2020 Cosponsor: Rep. Chris Pappas (D-NH-01) H.R. 6824 - 116th Congress - Second Session To amend the Internal Revenue Code of 1986 to provide for the carryover of the remaining 2020 balance in health flexible spending arrangements. Sponsor: Rep. Derek Kilmer (D-WA-06) H.R. 6855 - 116th Congress - Second Session Facilitating Virtual Visitation for Nursing Home Residents Act of 2020 Sponsor: Rep. Linda Sanchez (D-CA-38) H.R. 6857 - 116th Congress - Second Session COVID-19-Only Homes Organized for Resident Treatment Act of 2020 Sponsor: Rep. Tom Suozzi (D-NY-03) H.R. 6920 - 116th Congress - Second Session Keep Employees' Earnings Protected Act of 2020 Sponsor: Rep. Ross Spano (R-FL-15) H.R. 7008 - 116th Congress - Second Session Family Savings Flexibility Act Sponsor: Rep. Brad Wenstrup (R-OH-02) H.R. 7149 - 116th Congress - Second Session To amend the Internal Revenue Code of 1986 to provide special disposition rules for unused benefits in flexible spending arrangements of individuals for calendar year 2020. Sponsor: Rep. Gary Palmer (R-AL-06) H.R. 7233 - 116th Congress - Second Session Knowing the Efficiency and Efficacy of Permanent Telehealth Options Act of 2020 Sponsor: Rep. Troy Balderson (R-OH-12) H.R. 7242 - 116th Congress - Second Session To amend the Internal Revenue Code of 1986 to permit expenditures from health savings accounts for gym memberships and costs of home gym equipment, to repeal the requirement that health plan be high deductible, and for other purposes. Sponsor: Rep. John Curtis (R-UT-03) H.R. 7267 - 116th Congress - Second Session Patients Before Profits Act of 2020 Sponsor: Rep. Katie Porter (D-CA-45) Public Law 116-136(H.R. 748) - 116th Congress - First Session Third Coronavirus Stimulus Package Sponsor: Rep. Joe Courtney (D-CT-02)

H.R. 938, Bringing Low-cost Options and Competition while Keeping Incentives for New Generics (BLOCKING) Act of 2019, regarding all bio-pharmaceutical related provisions. H.R. 985, Fair Access for Safe and Timely (FAST) Generics Act of 2019, regarding all bio-pharmaceutical related provisions. H.R. 986, Protecting American with Preexisting Conditions Act of 2019, regarding all bio-pharmaceutical related provisions. H.R. 987, Marketing and Outreach Restoration to Empower Health Education Act of 2019, regarding all bio-pharmaceutical related provisions. H.R. 1010, Short-Term, Limited Duration Insurance (STLDI), regarding all bio-pharmaceutical related provisions. H.R. 1323, Rural Hospital Frontier Fairness Act, regarding all bio-pharmaceutical related provisions. H.R. 1385, State Allowance for a Variety of Exchanges (SAVE) Act, regarding all bio-pharmaceutical related provisions. H.R. 1386, Expanded Navigators Resources for Outreach, Learning, and Longevity (ENROLL) Act, regarding all bio-pharmaceutical related provisions. H.R. 1409, Transparency in All Health Care Pricing Act, regarding all bio-pharmaceutical related provisions. H.R. 1425, State Health Care Premium Reduction Act, regarding all bio-pharmaceutical related provisions. H.R. 1478, Insulin importation, regarding all bio-pharmaceutical related provisions. H.R. 1503, Orange Book Transparency Act, regarding all bio-pharmaceutical related provisions. H.R. 1506, Fair and Immediate Release (FAIR) of Generics Act, regarding all bio-pharmaceutical related provisions. H.R. 1520, Purple Book Continuity Act, regarding all bio-pharmaceutical related provisions. H.R. 2011, Protecting Access to Biosimilars Act of 2019, regarding all bio-pharmaceutical related provisions. H.R. 2038, State-based , Market-Oriented, Prescription Drug Negotiations Act of 2019, regarding all bio-pharmaceutical related provisions. H.R. 2064, Product Sample reporting, regarding all bio-pharmaceutical related provisions. S. 61, Safe and Affordable Drugs from Canada Act, regarding all bio-pharmaceutical related provisions. S. 97, Affordable and Safe Drug Importation Act, regarding all bio-pharmaceutical related provisions. S. 102, Prescription Drug Price Relief Act, regarding all bio-pharmaceutical related provisions. S. 344/H.R. 990, Hatch-Waxman Integrity Act, regarding all bio-pharmaceutical related provisions. S. 366/H.R. 1188, FLAT Prices Act- Reduced exclusivity period for certain price hikes, regarding all bio-pharmaceutical related provisions. S. 418, FDA Accountability for Public Safety Act, regarding all bio-pharmaceutical related provisions. S. 419, Protecting Americans from Dangerous Opioids Act, regarding all bio-pharmaceutical related provisions. S. 637, CURE High Drug Prices Act, regarding all bio-pharmaceutical related provisions. S. 657, Drug Price Transparency Act, regarding all bio-pharmaceutical related provisions. S. 658, Accelerated Drug Approval for Prescription Therapies Act, regarding all bio-pharmaceutical related provisions. S. 659, Biologic Patent Transparency Act, regarding all bio-pharmaceutical related provisions. S. 660, Transparency in Petitions Act, regarding all bio-pharmaceutical related provisions. S. 709, Establishes public dashboard for price and utilization of drugs purchased by federal programs, regarding all bio-pharmaceutical related provisions. S. 741 /H.R. 1730, Cancer Drug Parity Act, regarding all bio-pharmaceutical related provisions. S. 844, Short Competition Act, regarding all bio-pharmaceutical related provisions. S. 977, Transparent Drug Pricing Act of 2019, regarding all bio-pharmaceutical related provisions. S. 989, STEER Act, regarding all bio-pharmaceutical related provisions. S. 1140, A bill to amend the Public Health Service Act with respect to the treatment under section 351(k)(7) of such Act (relating to exclusivity for reference products) of certain products deemed to have a biological product license pursuant to section 7002 of the Biologics Price Competition and Innovation Act of 2009, regarding all bio-pharmaceutical related provisions. S.1169, FDA citizen petition, regarding all bio-pharmaceutical related provisions. S. 1209, A bill to amend the Federal Food, Drug, and Cosmetic Act with respect to approval of abbreviated new drug applications, regarding all bio-pharmaceutical related provisions. H.R. 2115, Public Disclosure of Drug Discounts Act, regarding all bio-pharmaceutical related provisions H.R.2296/S.1391, FAIR Drug Pricing Act, regarding all bio-pharmaceutical related provisions H.R.2700, Lowering Prescription Drug Costs and Extending Community Health Centers and other Health Priorities Act, regarding all bio-pharmaceutical related provisions H.R. 3223, Pharmacy Benefit Manager Accountability Study Act, regarding all bio-pharmaceutical related provisions S. 1361/H.R.2584, Preventive Health Savings Act, regarding all bio-pharmaceutical related provisions S. 1437, DTC Act, regarding all bio-pharmaceutical related provisions S.1532, Pharmacy Benefit Managers Accountability Study Act, regarding all bio-pharmaceutical related provisions S.1636, Ensuring Innovation Act, regarding all bio-pharmaceutical related provisions S. 1664, Prescription Drug Price Reporting Act, regarding all bio-pharmaceutical related provisions S. 1801, Affordable Medications Act, regarding all bio-pharmaceutical related provisions S. 1895, Lowering Health Costs Act, regarding all bio-pharmaceutical related provisions S. 1897, a bill to establish a process for updating the labeling of certain drugs with outdated labeling, regarding all bio-pharmaceutical related provisions S. 1897/H.R. 3523, End Price Gouging for Medications Act, regarding all bio-pharmaceutical related provisions S. 2004, Emergency Access to Insulin Act, regarding all bio-pharmaceutical related provisions H.R. 2279/S. 2546, Safe Step Act of 2019, regarding all bio-pharmaceutical related provisions H.R 748/S. 3548, Coronavirus Aid, Relief and Economic Security Act (CARES Act), regarding all bio-pharmaceutical provisions. H.R. 1425, State Health Care Premium Reduction Act, regarding all bio-pharmaceutical related provisions H.R. 6800, Health and Economic Recovery Omnibus Emergency Solutions (HEROES) Act, regarding all bio-pharmaceutical related provisions

H.R. 965: Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act of 2019 - Provisions related to Risk Evaluation and Mitigation Strategies (REMS) and limited distribution systems H.R. 985: FAST Generics Act of 2019 - Provisions related to Risk Evaluation and Mitigation Strategies (REMS) and limited distribution systems H.R. 1093: Stop Price Gouging Act - Provisions related to prescription drug pricing H.R. 1323: Rural Hospital Frontier Fairness Act - Provisions related to the 340B drug discount program H.R. 2296: FAIR Drug Pricing Act of 2019 / More Efficient Tools to Realize Information for Consumers Act - Provisions related to prescription drug pricing and transparency H.R. 2376: Prescription Pricing for the People Act of 2019 - Provisions related to prescription drug pricing transparency and pharmacy benefit managers H.R. 4812: Ensuring Compliance Against Drug Diversion Act of 2019 - Provisions related to registrations under the Controlled Substances Act H.R. 5239: Prescription Drug Price Reporting Act - Provisions related to prescription drug pricing transparency H.R. 5668: MODERN Labeling Act of 2020 - Provisions related to prescription drug labeling H.R. 6019: Cure the Coronavirus Act - Provisions related to FDA prescription drug approvals H.R. 6080: Preventing Drug Shortages Act - Provisions related to prescription drug shortage reporting requirements H.R. 6173: Covering Coronavirus Test Act of 2020 - Provisions related to medical device pricing and coverage H.R. 6213: No Cost for COVID-19 Testing Act - Provisions related to medical device pricing and coverage H.R. 6222: Ensuring Affordable COVID-19 Preventive Care Act of 2020 - Provisions related to prescription drug pricing and access H.R. 6231: Ensuring Access to COVID-19 Preventive Care Act of 2020 - Provisions related to prescription drug pricing and access H.R. 6253: To expand certain securities exemptions to respond to COVID-19, to establish an X-prize for creating an effective COVID-19 vaccine, and for other purposes - Provisions related to prescription drug research and development H.R. 6261: To provide for coverage of testing for COVID-19 at no cost sharing for Indians receiving health services through the Indian Health Service, and for other purposes - Provisions related to medical device pricing and coverage H.R. 6264: To prohibit price gouging during a state of emergency declaration, and for other purposes - Provisions related to prescription drug and medical device pricing H.R. 6351: To authorize the Secretary of Health and Human Services to administer vaccinations for COVID-19, once available, at no cost to the inoculated, in response to the COVID-19 outbreak, and for other purposes - Provisions related to prescription drug patient access and cost sharing H.R. 6390: To require the President to use authorities under the Defense Production Act of 1950 to require emergency production of medical equipment to address the COVID-19 outbreak - Provisions related to the Defense Production Act H.R. 6410: To direct the President to use authority under the Defense Production Act of 1950 to ensure an adequate supply equipment necessary for limiting the spread of COVID-19 - Provisions related to the Defense Production Act S. 61: Safe and Affordable Drugs from Canada Act of 2019 - Provisions related to importation S. 73: End Taxpayer Subsidies for Drug Ads Act - Provisions related to direct-to-consumer prescription drug advertising S. 340: Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act of 2019 - Provisions related to Risk Evaluation and Mitigation Strategies (REMS) and limited distribution systems S. 474: Stopping the Pharmaceutical Industry from Keeping Drugs Expensive (SPIKE) Act of 2019 - Provisions related to increases in the wholesale acquisition costs of prescription drugs S. 637: Combatting Unreasonable Rises and Excessively (CURE) High Drug Prices Act - Provisions related to prescription drug pricing and transparency S. 657: Drug Price Transparency Act - Provisions related to prescription drug pricing transparency and commercial market rebates S. 660: Efficiency and Transparency in Petitions Act - Provisions related to the FDA citizen petition process S. 801: Payment Commission Data Act of 2019 - Provisions related to prescription drug pricing transparency S. 977: Transparent Drug Pricing Act of 2019 - Provisions related to prescription drug pricing and foreign reference pricing S. 1089: Restoring Access to Medication Act of 2019 - Provisions related to prescription drug access S. 1227: Prescription Pricing for the People Act of 2019 - Provisions related to prescription drug pricing transparency and pharmacy benefit managers S. 1384: Prescription Drug Rebate Reform Act of 2019 - Provisions related to prescription drug pricing and negotiated rebates S. 1391: FAIR Drug Pricing Act of 2019 - Provisions related to prescription drug pricing and transparency S. 1437: Drug-price Transparency in Communications (DTC) Act - Provisions related to direct-to-consumer prescription drug advertising S. 1532: Pharmacy Benefit Manager Accountability Study Act of 2019 - Provisions related to prescription drug pricing transparency and pharmacy benefit managers S. 1567: Finding Orphan-disease Remedies With Antifungal Research and Development Act of 2019 - Provisions related to rare disease research and funding S1872/HR5076 Protecting Seniors Through Immunization Act S. 1897: A bill to establish a process for updating the labeling of certain drugs with outdated labeling - Provisions related to prescription drug labeling S. 2004: Emergency Access to Insulin Act of 2019 - Provisions related to prescription drug pricing S. 2103: Affordable Insulin Approvals Now Act - Provisions related to FDA prescription drug approvals S. 2161: Reciprocity Ensures Streamlined Use of Lifesaving Treatments Act of 2019 - Provisions related to reciprocity S. 2304: Strategies To Address Antibiotic Resistance Act - Provisions related to antimicrobial resistance (AMR) and other issues S. 2723: Mitigating Emergency Drug Shortages Act - Provisions related to prescription drug pricing transparency and other provisions S. 2897: Patient-Centered Outcomes Research Institute Reauthorization Act - Provisions related to PCORI reauthorization S. 3162: Affordable Drug Manufacturing Act of 2019 - Provisions related to prescription drug manufacturing S. 3166: Prescription Drug Affordability and Access Act - Provisions related to prescription drug pricing S. 3180: Responsibility in Drug Advertising Act of 2020 - Provisions related to prescription drug direct-to-consumer advertising S. 3384: Lowering Prescription Drug Prices for America's Seniors and Families Act of 2020 - Provisions related to prescription drug price negotiation, importation, and other issues S. 3439: Lower Health Insurance Deductibles Act - Provisions related to prescription drug pricing and insurance plan design S. 3432: Securing America's Medicine Cabinet Act of 2020 - Provisions related to advanced manufacturing and prescription drugs S. 3442: Care for COVID-19 Act - Provisions related to prescription drug pricing and access S. 3499: A bill to amend coverage requirements to ensure that no person incurs cost sharing when receiving a test to confirm a COVID-19 infection - Provisions related to medical device pricing and access S. 3505: A bill to require private health insurance to rapidly cover preventive services and vaccines related to the coronavirus - Provisions related to prescription drug pricing and access S. 3545: A bill to amend the Federal Food, Drug, and Cosmetic Act to provide for reciprocal marketing approval of certain drugs, biological products, and devices that are authorized to be lawfully marketed abroad, and for other purposes - Provisions related to FDA prescription drug marketing approvals S. 3564: A bill to amend title XIX of the Social Security Act to require States to provide medical assistance for COVID-19 treatment services for individuals who are diagnosed with COVID-19, and for other purposes - Provisions related to prescription drug pricing and access S. 3570: A bill to provide for the expedited procurement of equipment needed to combat COVID-19 under the Defense Production Act of 1950 - Provisions related to the Defense Production Act Transparency policy issues Drug cost and pricing policy issues Drug importation and counterfeiting policy issues HHS Safe Importation Action Plan Prescription drug take back and secure disposal policy issues Expanded access policy issues Antimicrobial resistance policy issues High deductible health plans/HSA policy issues Sharing of truthful and non-misleading information about medicines with healthcare professionals and payors Risk Evaluation and Mitigation Strategy (REMS) policy issues FDA modernization policy issues PDUFA implementation policy issues Monograph Reform CDC Programmatic Funding Restoration of HSA/FSAs 340B drug discount program policy issues Bipartisan Budget Act of 2018 (Public Law 115-123) - Part D provisions Patient assistance program policy issues Foreign manufacturing policy issues Biosimilar approval and reimbursement policy issues Cancer drug vial size policy issues Drug shortages policy issues Proposed Rule; Importation of Prescription Drugs (RIN 0910-AI45) Buy America and other associated issues related to procurement and sourcing of finished product and active pharmaceutical ingredients

Affordable Care Act (ACA), Affordability, ACA Regulations; ACA Stabilization; Health Reform, Risk Adjustment; opioids; Marketplace stability; Individual Market Reform; Health Care Costs; Mental Health; Small Business Plans, CRSs; SNPs; 42 CFR Part 2; Transparency; Silverloading; Health IT; Surprise billing; Transparency; Small Business; State Felxibility; Education and Enrollment; Prior Authorization; All payer claims database; Negotiated rate disclosure; Consumer facing App, disclosures; Provider directories; Medicare for All, Medicare Buy-in; Maternal Health; Senior's health care; Community Health NBPP (Notice Benefit and Payment Parameters); COVID-19 Response/Relief Packages; Healthcare Access/Privacy. H.R.1384 - 116th Congress (2019-2020) Medicare for All Act of 2019 Sponsor: Rep. Jayapal, Pramila [D-WA-7] (Introduced 02/27/2019) H.R.1520 - 116th Congress (2019-2020) Purple Book Continuity Act of 2019 Sponsor: Rep. Eshoo, Anna G. [D-CA-18] (Introduced 03/05/2019) S.1895 - 116th Congress (2019-2020) Lower Health Care Costs Act Sponsor: Sen. Alexander, Lamar [R-TN] (Introduced 06/19/2019) H.R.1046 - 116th Congress (2019-2020) Medicare Negotiation and Competitive Licensing Act of 2019 Sponsor: Rep. Doggett, Lloyd [D-TX-35] H.R. 3630 - 116th Congress (2019-2020) No Surprises Act Rep. Frank Pallone Jr. (D-NJ-6) H.R. 3439 - 116th Congress (2019-2020) PATIENT Act Rep. Donald S. Beyer, Jr. (D-VA-8) H.R. 3107 - 116th Congress (2019-2020) Improving Seniors Timely Access to Care Act of 2019 Rep. Suzane K. DelBene (D-WA-1) H.R. 2279 - 116th Congress (2019-2020) Safe Step Act Rep. Raul Ruiz (D-CA-36) S. 1895- 116th Congress (2019-2020) Lower Health Care Costs Act Sen. Lamar Alexander (R-TN) S. 2456 - 116th Congress (2019-2020) Safe Step Act Sen. Lisa Murkowski (R-AK) S. 2004 - 116th Congress (2019-2020) Ensuring FEDVIP and FLTCIP Coverage During Shutdown Act Rep. Elijah Cummings (D-MD-07) H.R. 2774 - 116th Congress (2019-2020) Primary Care Patient Protection Act of 2019 Rep. Brad Schneider (D-IL-10) H.R. 5826 - 116th Congress (2019-2020) Consumer Protection Against Surpirse Medical Bills Act of 2020 Rep. Richard Neal (D-MA-01) S. 3548 - 116th Congress Second Session Coronavirus Aid, Relief and Economic Security Act Sen. Mitch McConnell (R-KY) H.R. 5575 - 116th Congress Second Session Primary and Behavioral Health Care Access Act of 2020 Rep. Lauren Underwood (D-IL-14) H.R. 5688 - 116th Congress Second Session Reducing Administrative Costs and Burden in Health Care Act of 2020 Rep. Cindy Axne (D-IA-03) HR 5763 - 116th Congress Second Session National Telehealth Strategy and Data Advancement Act Rep. Greg Gianforte (R-MT-At Large) HR 5800 - 116th Congress Second Session Ban Surprise Billing Act Rep. Bobby Scott (D-VA-03) HR 5807 - 116th Congress Second Session Know Your Provider Act Rep. John Larson (D-CT-01) HR 5916 - 116th Congress Second Session Transparent Health Care Pricing Act of 2020 Rep. Mike Gallagher (R-WI-08) HR 6201 - 116th Congress Second Session First Coronavirus Response Act Rep. Nita Lowey (D-NY-17) HR 6336 - 116th Congress Second Session To amend title XI of the Social Security Act to provide for a waiver of payment reductions under the Medicare and Medicaid programs for certain nonapproved capital expenditures undertaken by health care facilities during the COVID-19 Emergency. HR 6336 - 116th Congress Second Session Care for COVID-19 Act Rep. Paul Ruiz (D-CA-36) HR 6299 - 116th Congress Second Session Rapid Coverage of COVID-19 Vaccine Act of 2020 HR 5817 - 116th Congress Second Session Fair and Honest Advance Cost Estimate for Patients Act of 2020 Rep. David Nunes (R-CA-22) HR 5816 - 116th Congress Second Session Continuing Care for Patients Act of 2020 Rep. Gwen Moore - (D-WI-4) HR 5089 - 116th Congress Second Session Better Information Act of 2020 Rep. Don Byer (D-VA-08) HR 5826 - 116th Congress Second Session Consumer Protections Against Surprise Medical Bills Act of 2020 Rep. Richard Neal (D-MA-01) HR 6004 - 116th Congress Second Session Transparency and Accountability in Health Care Costs and Prices Act of 2020 Rep. Dan Lipinski (D-IL-03) HR 6005 - 116th Congress Second Session Know the Price Act Rep. Tom Malinowski (D-NJ-07) HR 6132 - 116th Congress Second Session Social Determinants for Moms Act of 2020 Rep. Lucy McBath (D-GA-06) HR 6149 - 116th Congress Second Session Medicaid Report on Expansion of Access to coverage for Health Act REp. Joe Cunningham (D-SC-01) HR 6151 - 116th Congress Second Session CARING for Kids Act Rep. Abby Finkenauer (D-IA-01) HR 6173- 116th Congress Second Session Covering Coronavirus Test Act of 2020 Rep. Diana DeGette (D-CO-01) HR 6213 -116th Congress second Session No Cost for COVID-19 testing Act Rep. Fredrica Wilson (D-FL-24) HR 6222 - 116th Congress Second Session Ensuring Affordable COVID-19 Preventative Care Act of 2020 Rep. Jan Schakowsky (D-IL-09) HR 6232 - 116th Congress Second Session To Require the Secretary of Health and Human Services through the National Disaster Medical System, to provide for certain laboraty reimbursement for diagnostic testing for COVID-19 in uninsured individuals. Rep. Tony Cardenas (D-CA-29) HR 6231 - 116th Congress Second Session Ensuring Access to COVID-19 Preventative Care Act of 2020 Rep. Larry Buschon (R-In-08) HR 6244 - 116th Congress Second Session To amend titles XVIII and XIX to provide for coverage at no cost sharing of COVID-19 testing under the Medicaid program and Children's Health Insurance Program. Rep. Robin Kelly (D=IL-02) HR 6263 - 116th Congress Second Session To amend title XVII of the Social Security Act to Waive cost sharing under the Medicare program for certain visits relating to testing for COVID-19 Rep. John Sarbanes (D-MD-03)

H.R. 965: Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act of 2019 - Provisions related to Risk Evaluation and Mitigation Strategies (REMS) and limited distribution systems H.R. 985: FAST Generics Act of 2019 - Provisions related to Risk Evaluation and Mitigation Strategies (REMS) and limited distribution systems H.R. 1093: Stop Price Gouging Act - Provisions related to prescription drug pricing H.R. 1323: Rural Hospital Frontier Fairness Act - Provisions related to the 340B drug discount program H.R. 2296: FAIR Drug Pricing Act of 2019 / More Efficient Tools to Realize Information for Consumers Act - Provisions related to prescription drug pricing and transparency H.R. 2376: Prescription Pricing for the People Act of 2019 - Provisions related to prescription drug pricing transparency and pharmacy benefit managers H.R. 4812: Ensuring Compliance Against Drug Diversion Act of 2019 - Provisions related to registrations under the Controlled Substances Act H.R. 5239: Prescription Drug Price Reporting Act - Provisions related to prescription drug pricing transparency H.R. 5382: To create a mechanism whereby insulin manufacturers may sell directly to consumers at current net prices. - Provisions related to prescription drug pricing H.R. 5668: MODERN Labeling Act of 2020 - Provisions related to prescription drug labeling H.R. 6019: Cure the Coronavirus Act - Provisions related to FDA prescription drug approvals H.R. 6080: Preventing Drug Shortages Act - Provisions related to prescription drug shortage reporting requirements H.R. 6173: Covering Coronavirus Test Act of 2020 - Provisions related to medical device pricing and coverage H.R. 6213: No Cost for COVID-19 Testing Act - Provisions related to medical device pricing and coverage H.R. 6222: Ensuring Affordable COVID-19 Preventive Care Act of 2020 - Provisions related to prescription drug pricing and access H.R. 6231: Ensuring Access to COVID-19 Preventive Care Act of 2020 - Provisions related to prescription drug pricing and access H.R. 6253: To expand certain securities exemptions to respond to COVID-19, to establish an X-prize for creating an effective COVID-19 vaccine, and for other purposes - Provisions related to prescription drug research and development H.R. 6261: To provide for coverage of testing for COVID-19 at no cost sharing for Indians receiving health services through the Indian Health Service, and for other purposes - Provisions related to medical device pricing and coverage H.R. 6264: To prohibit price gouging during a state of emergency declaration, and for other purposes - Provisions related to prescription drug and medical device pricing H.R. 6351: To authorize the Secretary of Health and Human Services to administer vaccinations for COVID-19, once available, at no cost to the inoculated, in response to the COVID-19 outbreak, and for other purposes - Provisions related to prescription drug patient access and cost sharing H.R. 6390: To require the President to use authorities under the Defense Production Act of 1950 to require emergency production of medical equipment to address the COVID-19 outbreak - Provisions related to the Defense Production Act H.R. 6410: To direct the President to use authority under the Defense Production Act of 1950 to ensure an adequate supply equipment necessary for limiting the spread of COVID-19 - Provisions related to the Defense Production Act S. 61: Safe and Affordable Drugs from Canada Act of 2019 - Provisions related to importation S. 73: End Taxpayer Subsidies for Drug Ads Act - Provisions related to direct-to-consumer prescription drug advertising S. 340: Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act of 2019 - Provisions related to Risk Evaluation and Mitigation Strategies (REMS) and limited distribution systems S. 474: Stopping the Pharmaceutical Industry from Keeping Drugs Expensive (SPIKE) Act of 2019 - Provisions related to increases in the wholesale acquisition costs of prescription drugs S. 637: Combatting Unreasonable Rises and Excessively (CURE) High Drug Prices Act - Provisions related to prescription drug pricing and transparency S. 657: Drug Price Transparency Act - Provisions related to prescription drug pricing transparency and commercial market rebates S. 660: Efficiency and Transparency in Petitions Act - Provisions related to the FDA citizen petition process S. 801: Payment Commission Data Act of 2019 - Provisions related to prescription drug pricing transparency S. 977: Transparent Drug Pricing Act of 2019 - Provisions related to prescription drug pricing and foreign reference pricing S. 1089: Restoring Access to Medication Act of 2019 - Provisions related to prescription drug access S. 1227: Prescription Pricing for the People Act of 2019 - Provisions related to prescription drug pricing transparency and pharmacy benefit managers S. 1384: Prescription Drug Rebate Reform Act of 2019 - Provisions related to prescription drug pricing and negotiated rebates S. 1391: FAIR Drug Pricing Act of 2019 - Provisions related to prescription drug pricing and transparency S. 1437: Drug-price Transparency in Communications (DTC) Act - Provisions related to direct-to-consumer prescription drug advertising S. 1532: Pharmacy Benefit Manager Accountability Study Act of 2019 - Provisions related to prescription drug pricing transparency and pharmacy benefit managers S. 1567: Finding Orphan-disease Remedies With Antifungal Research and Development Act of 2019 - Provisions related to rare disease research and funding S. 1897: A bill to establish a process for updating the labeling of certain drugs with outdated labeling - Provisions related to prescription drug labeling S. 2004: Emergency Access to Insulin Act of 2019 - Provisions related to prescription drug pricing S. 2103: Affordable Insulin Approvals Now Act - Provisions related to FDA prescription drug approvals S. 2161: Reciprocity Ensures Streamlined Use of Lifesaving Treatments Act of 2019 - Provisions related to reciprocity S. 2304: Strategies To Address Antibiotic Resistance Act - Provisions related to antimicrobial resistance (AMR) and other issues S. 2723: Mitigating Emergency Drug Shortages Act - Provisions related to prescription drug pricing transparency and other provisions S. 2897: Patient-Centered Outcomes Research Institute Reauthorization Act - Provisions related to PCORI reauthorization S. 3162: Affordable Drug Manufacturing Act of 2019 - Provisions related to prescription drug manufacturing S. 3166: Prescription Drug Affordability and Access Act - Provisions related to prescription drug pricing S. 3180: Responsibility in Drug Advertising Act of 2020 - Provisions related to prescription drug direct-to-consumer advertising S. 3384: Lowering Prescription Drug Prices for America's Seniors and Families Act of 2020 - Provisions related to prescription drug price negotiation, importation, and other issues S. 3439: Lower Health Insurance Deductibles Act - Provisions related to prescription drug pricing and insurance plan design S. 3432: Securing America's Medicine Cabinet Act of 2020 - Provisions related to advanced manufacturing and prescription drugs S. 3442: Care for COVID-19 Act - Provisions related to prescription drug pricing and access S. 3468 Preventing Essential Medical Device Shortages Act of 2020 - Provisions related to medical device shortage reporting requirements S. 3499: A bill to amend coverage requirements to ensure that no person incurs cost sharing when receiving a test to confirm a COVID-19 infection - Provisions related to medical device pricing and access S. 3505: A bill to require private health insurance to rapidly cover preventive services and vaccines related to the coronavirus - Provisions related to prescription drug pricing and access S. 3545: A bill to amend the Federal Food, Drug, and Cosmetic Act to provide for reciprocal marketing approval of certain drugs, biological products, and devices that are authorized to be lawfully marketed abroad, and for other purposes - Provisions related to FDA prescription drug marketing approvals S. 3564: A bill to amend title XIX of the Social Security Act to require States to provide medical assistance for COVID-19 treatment services for individuals who are diagnosed with COVID-19, and for other purposes - Provisions related to prescription drug pricing and access S. 3568: To require the President to use authorities under the Defense Production Act of 1950 to require emergency production of medical equipment to address the COVID-19 outbreak - Provisions related to the Defense Production Act S. 3570: A bill to provide for the expedited procurement of equipment needed to combat COVID-19 under the Defense Production Act of 1950 - Provisions related to the Defense Production Act Transparency policy issues Drug cost and pricing policy issues Drug importation and counterfeiting policy issues HHS Safe Importation Action Plan Prescription drug take back and secure disposal policy issues Policy issues related to prescription drug abuse and opioids Expanded access policy issues Antimicrobial resistance policy issues High deductible health plans/HSA policy issues Sharing of truthful and non-misleading information about medicines with healthcare professionals and payors Risk Evaluation and Mitigation Strategy (REMS) policy issues FDA modernization policy issues PDUFA implementation policy issues 340B drug discount program policy issues Bipartisan Budget Act of 2018 (Public Law 115-123) - Part D provisions Patient assistance program policy issues Foreign manufacturing policy issues Biosimilar approval and reimbursement policy issues Cancer drug vial size policy issues Drug shortages policy issues Proposed Rule; Importation of Prescription Drugs (RIN 0910-AI45) Buy America and other associated issues related to procurement and sourcing of finished product and active pharmaceutical ingredients

S. 1895 - Lower Health Care Costs Act H.R. 2668 - Special Diabetes Program Reauthorization Act of 2019 H.R. 2680 - Special Diabetes Program for Indians Reauthorization Act of 2019 H.R. 2328 - Reauthorizing and Extending Americas Community Health Act (REACH Act) H.R. 965 - CREATES Act of 2019 S. 2543 - The Prescription Drug Pricing Reduction Act of 2019 S. 2199, H.R. 4906 - Insulin Price Reduction Act S. 2004, H.R. 4010 -- Emergency Access to Insulin Act of 2019 H.R. 3 - Lower Drug Costs Now Act of 2019 S. 2855 - Insulin Affordability Data Collection Act H.R. 19, S. 3129 - Lower Costs, More Cures Act of 2019 Issues and legislation related to drug pricing, specifically as it relates to insulin Issues and legislation related to a passthrough of any/all savings to beneficiaries using insulin in Medicare Part D. Issues and legislation related to providing flexibility in the split of a deductible between devices and prescription drugs Issues related to the importance of preserving health insurance protections for individuals with pre-existing conditions. H.R. 5254 - Diabetic Vision Loss and Blindness Prevention Act of 2019 Issues relates to expanding telehealth under Medicare for the purposes of qualifying visits for insulin pumps and continuous glucose monitors. S. 3548, H.R. 748 - CARES Act

Client expense: $190,000 · Firm income: Not reported

Affordable Care Act (ACA); Affordability, ACA Regulations; ACA Stabilization; Health Reform; Risk Adjustment; Opioids; Marketplace Stability; Individual Market Reform; Health Care Costs; Mental Health; Small Business Plans; CSRs; SNPs; 42 CFR Part 2; Transparency; Silverloading; Health IT; Surprise billing, Transparency, Small Business, State Flexibility; Education,and Enrollment; Prior Authorization; All payer claims database; Negotiated rate disclosure; Consumer-facing app disclosures; Provider directories; Medicare for All; Medicare Buy-in; Maternal health; Senior's health care; Community health; NBPP (Notice Benefit and Payment Parameters), COVID-19 Response/Relief Packages, Healthcare access/privacy H.R.1384 - 116th Congress (2019-2020) Medicare for All Act of 2019 Sponsor: Rep. Jayapal, Pramila [D-WA-7] (Introduced 02/27/2019) H.R.2003 - 116th Congress (2019-2020) Ensuring FEHBP Coverage During Shutdowns Act Sponsor: Rep. Cummings, Elijah E. [D-MD-7] (Introduced 04/01/2019) H.R.2004 - 116th Congress (2019-2020) Ensuring FEDVIP and FLTCIP Coverage During Shutdowns Act Sponsor: Rep. Cummings, Elijah E. [D-MD-7] (Introduced 04/01/2019) S.973 - 116th Congress (2019-2020) Ensuring FEDVIP and FLTCIP Coverage During Shutdowns Act Sponsor: Sen. Smith, Tina [D-MN] (Introduced 04/01/2019) S.971 - 116th Congress (2019-2020) Ensuring FEHBP Coverage During Shutdowns Act Sponsor: Sen. Smith, Tina [D-MN] (Introduced 04/01/2019) H.R.1520 - 116th Congress (2019-2020) Purple Book Continuity Act of 2019 Sponsor: Rep. Eshoo, Anna G. [D-CA-18] (Introduced 03/05/2019) S.1895 - 116th Congress (2019-2020) Lower Health Care Costs Act Sponsor: Sen. Alexander, Lamar [R-TN] (Introduced 06/19/2019) H.R.1046 - 116th Congress (2019-2020) Medicare Negotiation and Competitive Licensing Act of 2019 Sponsor: Rep. Doggett, Lloyd [D-TX-35] H.R.3630 - 116th Congress (2019-2020) No Surprises Act Sponsor: Rep. Pallone, Frank, Jr. [D-NJ-6] H.R.3439 - 116th Congress (2019-2020) PATIENT Act Sponsor: Rep. Beyer, Donald S., Jr. [D-VA-8] H.R.3107 - 116th Congress (2019-2020) Improving Seniors' Timely Access to Care Act of 2019 Sponsor: Rep. DelBene, Suzan K. [D-WA-1] H.R.2279 - 116th Congress (2019-2020) Safe Step Act Sponsor: Rep. Ruiz, Raul [D-CA-36] S.1895 - 116th Congress (2019-2020) Lower Health Care Costs Act Sponsor: Sen. Alexander, Lamar [R-TN] S. 2546 - 116th Congress (2019-2020) Safe Step Act Sponsor: Sen. Lisa Murkowski (R-AK) S. 2004 - 116th Congress (2019-2020) Ensuring FEDVIP and FLTCIP Coverage During Shutdowns Act Sponsor: Rep. Elijah Cummings (D-MD-07) H.R. 2774 - 116th Congress (2019-2020) Primary Care Patient Protection Act of 2019 Sponsor: Rep. Brad Schneider (D-IL-10) H.R. 5826 - 116th Congress - Second Session Consumer Protections Against Surprise Medical Bills Act of 2020 Sponsor: Rep. Richard Neal(D-MA-01) S. 3548 - 116th Congress - Second Session Coronavirus Aid, Relief, and Economic Security Act Sponsor: Sen. Mitch McConnell (R-KY) H.R. 5551 - 116th Congress - Second Session Ensuring Child Health Coverage Compensation in Divorce Act of 2020 Sponsor: Del. Eleanor Holmes Norton (D-DC At-Large) H.R. 5575 - 116th Congress - Second Session Primary and Behavioral Health Care Access Act of 2020 Sponsor: Rep. Lauren Underwood (D-IL-14) H.R. 5688 - 116th Congress - Second Session Reducing Administrative Costs and Burdens in Health Care Act of 2020 Sponsor: Rep. Cindy Axne (D-IA-03) H.R. 5754 - 116th Congress - Second Session Rural ER Access Act Sponsor: Rep. Mark Green (R-TN-07) H.R. 5763 - 116th Congress - Second Session National Telehealth Strategy and Data Advancement Act Sponsor: Rep. Greg Gianforte (R-MT At-Large) H.R. 5800 - 116th Congress - Second Session Ban Surprise Billing Act Sponsor: Rep. Bobby Scott (D-VA-03) H.R. 5807 - 116th Congress - Second Session Know Your Provider Act of 2020 Sponsor: Rep. John Larson (D-CT-01) H.R. 5916 - 116th Congress - Second Session Transparent Health Care Pricing Act of 2020 Sponsor: Rep. Mike Gallagher (R-WI-08) H.R. 6201 - 116th Congress - Second Session First Coronavirus Response Act Sponsor: Rep. Nita Lowey (D-NY-17) H.R. 6336 - 116th Congress - Second Session To amend title XI of the Social Security Act to provide for a waiver of payment reductions under the Medicare and Medicaid programs for certain nonapproved capital expenditures undertaken by health care facilities during the COVID-19 emergency. Sponsor: Rep. Dan Bishop (R-NC-09) H.R. 6311 - 116th Congress - Second Session Care for COVID-19 Act Sponsor: Rep. Raul Ruiz (D-CA-36) H.R. 6299 - 116th Congress - Second Session Rapid Coverage of COVID-19 Vaccine Act of 2020 H.R. 5817 - 116th Congress - Second Session Fair and Honest Advance Cost Estimate for Patients Act of 2020 Sponsor: Rep. Devin Nunes (R-CA-22) H.R. 5816 - 116th Congress - Second Session Continuing Care for Patients Act of 2020 Sponsor: Rep. Gwen Moore (D-WI-04) HR. 5809 - 116th Congress - Second Session Better Information Act of 2020 Sponsor: Rep. Don Beyer (D-VA-08) H.R. 5826 -116th Congress - Second Session Consumer Protections Against Surprise Medical Bills Act of 2020 Sponsor: Rep. Richard Neal (D-MA-01) H.R. 5924 - 116th Congress - Second Session To amend the Public Health Service Act to authorize a loan repayment program to encourage specialty medicine physicians to serve in rural communities experiencing a shortage of specialty medicine physicians, and for other purposes. Sponsor: Rep. David McKinley (R-WV-01) H.R. 6004 - 116th Congress - Second Session Transparency and Accountability in Health Care Costs and Prices Act of 2020 Sponsor: Rep. Dan Lipinski (D-IL-03) H.R. 6005 - 116th Congress - Second Session Know the Price Act Sponsor: Rep. Tom Malinowski (D-NJ-07) H.R. 6132 - 116th Congress - Second Session Social Determinants for Moms Act of 2020 Sponsor: Rep. Lucy McBath (D-GA-06) H.R. 6135 - 116th Congress - Second Session No More Narrow Networks Act of 2020 Sponsor: Rep. Jan Schakowsky (D-IL-09) H.R. 6136 - 116th Congress - Second Session Protecting Consumers from Unreasonable Rates Act of 2020 Sponsor: Rep. Jan Schakowsky (D-IL-09) H.R. 6137 - 116th Congress - Second Session Innovative Maternal Payment And Coverage To Save Moms Act Sponsor: Rep. Jan Schakowsky (D-IL-09) H.R. 6138 - 116th Congress - Second Session Tech to Save Moms Act Sponsor: Rep. Eddie Bernice Johnson (D-TX-30) H.R. 6149 - 116th Congress - Second Session Medicaid Report on Expansion of Access to Coverage for Health Act Sponsor: Rep. Joe Cunningham (D-SC-01) H.R. 6151 - 116th Congress - Second Session CARING for Kids Act Sponsor: Rep. Abby Finkenauer (D-IA-01) H.R. 6173 - 116th Congress - Second Session Covering Coronavirus Test Act of 2020 Sponsor: Rep. Diana DeGette (D-CO-01) H.R. 6213 - 116th Congress - Second Session No Cost for COVID-19 Testing Act Sponsor: Rep. Frederica Wilson (D-FL-24) H.R. 6222 - 116th Congress - Second Session Ensuring Affordable COVID-19 Preventive Care Act of 2020 Sponsor: Rep. Jan Schakowsky (D-IL-09) H.R. 6232 - 116th Congress - Second Session To require the Secretary of Health and Human Services, through the National Disaster Medical System, to provide for certain laboratory reimbursement for diagnostic testing for COVID-19 in uninsured individuals. Sponsor: Rep. Tony Cardenas (D-CA-29) H.R. 6231 - 116th Congress - Second Session Ensuring Access to COVID-19 Preventive Care Act of 2020 Sponsor: Rep. Larry Bucshon (R-IN-08) H.R. 6244 - 116th Congress - Second Session To amend titles XVIII and XIX to provide for coverage at no cost sharing of COVID-19 testing under the Medicaid program and Children's Health Insurance Program. Sponsor: Rep. Robin Kelly (D-IL-02) H.R. 6263 - 116th Congress - Second Session To amend title XVIII of the Social Security Act to waive cost sharing under the Medicare program for certain visits relating to testing for COVID-19. Sponsor: Rep. John Sarbanes (D-MD-03) H.R. 6282 - 116th Congress - Second Session Commission on America's Medical Security Act Sponsor: Rep. Raul Ruiz (D-CA-36) H.R. 6283 - 116th Congress - Second Session Good Samaritan Health Professionals Act of 2020 Sponsor: Rep. Raul Ruiz (D-CA-36) H.R. 1379 - 116th Congress - First Session Ensuring Lasting Smiles Act Rep. Collin Peterson (D-MN-07)

H.R. 938, Bringing Low-cost Options and Competition while Keeping Incentives for New Generics (BLOCKING) Act of 2019, regarding all bio-pharmaceutical related provisions. H.R. 985, Fair Access for Safe and Timely (FAST) Generics Act of 2019, regarding all bio-pharmaceutical related provisions. H.R. 986, Protecting American with Preexisting Conditions Act of 2019, regarding all bio-pharmaceutical related provisions. H.R. 987, Marketing and Outreach Restoration to Empower Health Education Act of 2019, regarding all bio-pharmaceutical related provisions. H.R. 1010, Short-Term, Limited Duration Insurance (STLDI), regarding all bio-pharmaceutical related provisions. H.R. 1323, Rural Hospital Frontier Fairness Act, regarding all bio-pharmaceutical related provisions. H.R. 1385, State Allowance for a Variety of Exchanges (SAVE) Act, regarding all bio-pharmaceutical related provisions. H.R. 1386, Expanded Navigators Resources for Outreach, Learning, and Longevity (ENROLL) Act, regarding all bio-pharmaceutical related provisions. H.R. 1409, Transparency in All Health Care Pricing Act, regarding all bio-pharmaceutical related provisions. H.R. 1425, State Health Care Premium Reduction Act, regarding all bio-pharmaceutical related provisions. H.R. 1478, Insulin importation, regarding all bio-pharmaceutical related provisions. H.R. 1503, Orange Book Transparency Act, regarding all bio-pharmaceutical related provisions. H.R. 1506, Fair and Immediate Release (FAIR) of Generics Act, regarding all bio-pharmaceutical related provisions. H.R. 1520, Purple Book Continuity Act, regarding all bio-pharmaceutical related provisions. H.R. 2011, Protecting Access to Biosimilars Act of 2019, regarding all bio-pharmaceutical related provisions. H.R. 2038, State-based , Market-Oriented, Prescription Drug Negotiations Act of 2019, regarding all bio-pharmaceutical related provisions. H.R. 2064, Product Sample reporting, regarding all bio-pharmaceutical related provisions. S. 61, Safe and Affordable Drugs from Canada Act, regarding all bio-pharmaceutical related provisions. S. 97, Affordable and Safe Drug Importation Act, regarding all bio-pharmaceutical related provisions. S. 102, Prescription Drug Price Relief Act, regarding all bio-pharmaceutical related provisions. S. 344/H.R. 990, Hatch-Waxman Integrity Act, regarding all bio-pharmaceutical related provisions. S. 366/H.R. 1188, FLAT Prices Act- Reduced exclusivity period for certain price hikes, regarding all bio-pharmaceutical related provisions. S. 418, FDA Accountability for Public Safety Act, regarding all bio-pharmaceutical related provisions. S. 419, Protecting Americans from Dangerous Opioids Act, regarding all bio-pharmaceutical related provisions. S. 637, CURE High Drug Prices Act, regarding all bio-pharmaceutical related provisions. S. 657, Drug Price Transparency Act, regarding all bio-pharmaceutical related provisions. S. 658, Accelerated Drug Approval for Prescription Therapies Act, regarding all bio-pharmaceutical related provisions. S. 659, Biologic Patent Transparency Act, regarding all bio-pharmaceutical related provisions. S. 660, Transparency in Petitions Act, regarding all bio-pharmaceutical related provisions. S. 709, Establishes public dashboard for price and utilization of drugs purchased by federal programs, regarding all bio-pharmaceutical related provisions. S. 741 /H.R. 1730, Cancer Drug Parity Act, regarding all bio-pharmaceutical related provisions. S. 844, Short Competition Act, regarding all bio-pharmaceutical related provisions. S. 977, Transparent Drug Pricing Act of 2019, regarding all bio-pharmaceutical related provisions. S. 989, STEER Act, regarding all bio-pharmaceutical related provisions. S. 1140, A bill to amend the Public Health Service Act with respect to the treatment under section 351(k)(7) of such Act (relating to exclusivity for reference products) of certain products deemed to have a biological product license pursuant to section 7002 of the Biologics Price Competition and Innovation Act of 2009, regarding all bio-pharmaceutical related provisions. S.1169, FDA citizen petition, regarding all bio-pharmaceutical related provisions. S. 1209, A bill to amend the Federal Food, Drug, and Cosmetic Act with respect to approval of abbreviated new drug applications, regarding all bio-pharmaceutical related provisions. H.R. 2115, Public Disclosure of Drug Discounts Act, regarding all bio-pharmaceutical related provisions H.R.2296/S.1391, FAIR Drug Pricing Act, regarding all bio-pharmaceutical related provisions H.R.2700, Lowering Prescription Drug Costs and Extending Community Health Centers and other Health Priorities Act, regarding all bio-pharmaceutical related provisions H.R. 3223, Pharmacy Benefit Manager Accountability Study Act, regarding all bio-pharmaceutical related provisions S. 1361/H.R.2584, Preventive Health Savings Act, regarding all bio-pharmaceutical related provisions S. 1437, DTC Act, regarding all bio-pharmaceutical related provisions S.1532, Pharmacy Benefit Managers Accountability Study Act, regarding all bio-pharmaceutical related provisions S.1636, Ensuring Innovation Act, regarding all bio-pharmaceutical related provisions S. 1664, Prescription Drug Price Reporting Act, regarding all bio-pharmaceutical related provisions S. 1801, Affordable Medications Act, regarding all bio-pharmaceutical related provisions S. 1895, Lowering Health Costs Act, regarding all bio-pharmaceutical related provisions S. 1897, a bill to establish a process for updating the labeling of certain drugs with outdated labeling, regarding all bio-pharmaceutical related provisions S. 1897/H.R. 3523, End Price Gouging for Medications Act, regarding all bio-pharmaceutical related provisions S. 2004, Emergency Access to Insulin Act, regarding all bio-pharmaceutical related provisions H.R. 2279/S. 2546, Safe Step Act of 2019, regarding all bio-pharmaceutical related provisions H.R 748/S. 3548, Coronavirus Aid, Relief and Economic Security Act (CARES Act), regarding all bio-pharmaceutical related provisions

H.R. 447: Affordable and Safe Prescription Drug Importation Act - Provisions related to importation H.R. 478: Safe and Affordable Drugs from Canada Act of 2019 - Provisions related to importation H.R. 965: Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act of 2019 - Provisions related to Risk Evaluation and Mitigation Strategies (REMS) and limited distribution systems H.R. 985: FAST Generics Act of 2019 - Provisions related to Risk Evaluation and Mitigation Strategies (REMS) and limited distribution systems H.R. 1093: Stop Price Gouging Act - Provisions related to prescription drug pricing H.R. 1478: Affordable Insulin Act of 2019 - Provisions related to importation H.R. 1506: Fair and Immediate Release (FAIR) of Generic Drugs Act - Provisions related to generic prescription drug approvals H.R. 1922: Restoring Access to Medication Act of 2019 - Provisions related to prescription drug access H.R. 2064: To amend title XI of the Social Security Act to require manufacturers of certain drugs, devices, biologicals, and medical supplies to report on product samples provided to certain health care providers, and for other purposes - Provisions related to prescription drug samples H.R. 2069: Stopping the Pharmaceutical Industry from Keeping Drugs Expensive (SPIKE) Act of 2019 - Provisions related to increases in the wholesale acquisition costs of prescription drugs H.R. 2087: Drug Price Transparency Act - Provisions related to prescription drug pricing and transparency H.R. 2113: Prescription Drug STAR Act - Provisions related to prescription drug pricing, reporting and product samples H.R. 2296: FAIR Drug Pricing Act of 2019 / More Efficient Tools to Realize Information for Consumers Act - Provisions related to prescription drug pricing and transparency H.R. 2376: Prescription Pricing for the People Act of 2019 - Provisions related to prescription drug pricing transparency and pharmacy benefit managers H.R. 2734: Safer Prescribing of Controlled Substances Act - Provisions related to the prescribing of prescription drugs H.R. 3223: Pharmacy Benefit Manager Accountability Study Act of 2019 - Provisions related to prescription drug pricing transparency and pharmacy benefit managers H.R. 3327: Drug Price Transparency for Medicare Patients Act of 2019 - Provisions related to direct-to-consumer prescription drug advertising H.R. 3415: Real-Time Beneficiary Drug Cost Bill - Provisions related to drug pricing transparency H.R. 3947: Competition Prescription Act of 2019 - Provisions related to prescription drug pricing, patents, and other provisions H.R. 4106: Responsibility in Drug Advertising Act of 2019 - Provisions related to direct-to-consumer prescription drug advertising H.R. 4158: CURE High Drug Prices Act - Provisions related to prescription drug pricing and transparency H.R. 4244: MAGIC Act - Provisions related to FDA approval pathways H.R. 4439: Creating Hope Reauthorization Act - Provisions related to rare disease priority review vouchers H.R. 4538: Closing Loopholes for Orphan Drugs Act - Provisions related to 340B prescription drug exclusions H.R. 4633: Investing in Safety and Innovation Act of 2019 - Provisions related to FDA programs reauthorization H.R. 4640: Affordable Pricing for Taxpayer-Funded Prescription Drugs Act of 2019 - Provisions related to prescription drug pricing and negotiation H.R. 4667: Biomedical Innovation Expansion Act of 2019 - Provisions related to NIH programs reauthorization H.R. 4710: Pharmaceutical Independence Long-Term Readiness Reform Act - Provisions related to the supply chain H.R. 4711: No Tax Breaks for Drug Ads Act - Provisions related to direct-to-consumer prescription drug advertising H.R. 4812: Ensuring Compliance Against Drug Diversion Act of 2019 - Provisions related to registrations under the Controlled Substances Act H.R. 4866: National Centers of Excellence in Continuous Pharmaceutical Manufacturing Act of 2019 - Provisions related to designation of universities as centers of excellence supporting manufacturing H.R. 4963: Stop the Importation and Manufacturing of Synthetic Analogues Act of 2019 - Provisions related to synthetic analogues H.R. 5031: Medical Innovation Act of 2019 - Provisions related to prescription drug manufacturer taxation and supplemental fees H.R. 5198: Patients' Right to Know Their Medication Act of 2019 - Provisions related to prescription drug labeling H.R. 5239: Prescription Drug Price Reporting Act - Provisions related to prescription drug pricing transparency H.R. 5304: PBM Transparency in Prescription Drug Costs Act - Provisions related to prescription drug pricing transparency H.R. 5381: International Pharmaceutical Transparency Act of 2019 - Provisions related to prescription drug labeling H.R. 5442: To amend title XXVII of the Public Health Service Act and title XVIII of the Social Security Act to require pharmacies to disclose any differential between the cost of a prescription drug based on whether certain individuals use prescription drug coverage to acquire such drug, and for other purposes. - Provisions related to prescription drug pricing and transparency H.R. 5497: Conditional Approval Act - Provisions related to approval pathway S. 61: Safe and Affordable Drugs from Canada Act of 2019 - Provisions related to importation S. 73: End Taxpayer Subsidies for Drug Ads Act - Provisions related to direct-to-consumer prescription drug advertising S. 97: Affordable and Safe Prescription Drug Importation Act - Provisions related to importation S. 340: Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act of 2019 - Provisions related to Risk Evaluation and Mitigation Strategies (REMS) and limited distribution systems S. 378: Stop Price Gouging Act - Provisions related to prescription drug pricing S. 474: Stopping the Pharmaceutical Industry from Keeping Drugs Expensive (SPIKE) Act of 2019 - Provisions related to increases in the wholesale acquisition costs of prescription drugs S. 637: Combatting Unreasonable Rises and Excessively (CURE) High Drug Prices Act - Provisions related to prescription drug pricing and transparency S. 657: Drug Price Transparency Act - Provisions related to prescription drug pricing transparency and commercial market rebates S. 658: Accelerated Drug Approval for Prescription Therapies Act - Provisions related to FDA drug approvals S. 660: Efficiency and Transparency in Petitions Act - Provisions related to the FDA citizen petition process S. 1140: Protecting Access to Biosimilars Act of 2019 - Provisions related to biological products S. 1227: Prescription Pricing for the People Act of 2019 - Provisions related to prescription drug pricing transparency and pharmacy benefit managers S. 1250: American Cures Act - Provisions related to pharmaceutical research and development S. 1391: FAIR Drug Pricing Act of 2019 - Provisions related to prescription drug pricing and transparency S. 1437: Drug-price Transparency in Communications (DTC) Act - Provisions related to direct-to-consumer prescription drug advertising S. 1532: Pharmacy Benefit Manager Accountability Study Act of 2019 - Provisions related to prescription drug pricing transparency and pharmacy benefit managers S. 2004: Emergency Access to Insulin Act of 2019 - Provisions related to prescription drug pricing S. 2161: Reciprocity Ensures Streamlined Use of Lifesaving Treatments Act of 2019 - Provisions related to reciprocity S. 2723: Mitigating Emergency Drug Shortages Act - Provisions related to prescription drug pricing transparency and other provisions S. 2897: Patient-Centered Outcomes Research Institute Reauthorization Act - Provisions related to PCORI reauthorization Transparency policy issues Drug cost and pricing policy issues Drug importation and counterfeiting policy issues HHS Safe Importation Action Plan Prescription drug take back and secure disposal policy issues Policy issues related to prescription drug abuse and opioids Expanded access policy issues Generic drug approval process policy issues High deductible health plans/HSA policy issues Sharing of truthful and non-misleading information about medicines with healthcare professionals and payors Risk Evaluation and Mitigation Strategy (REMS) policy issues FDA modernization policy issues PDUFA implementation policy issues 340B drug discount program policy issues Bipartisan Budget Act of 2018 (Public Law 115-123) - Part D provisions Patient assistance program policy issues Foreign manufacturing policy issues Biosimilar approval and reimbursement policy issues Drug compounding policy issues including federal oversight of compounded drugs Cancer drug vial size policy issues TRICARE pharmacy pilot program Drug shortages policy issues Request for Information: HHS Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs (RIN 0991-ZA49) Proposed Rule; Importation of Prescription Drugs (RIN 0910-AI45) Monograph Reform, HSA/FSAs S 2740 - Over-the-Counter Monograph Safety S1872/HR5076, Protecting Seniors Through Immunization Act S1654/HR1973, Vaccine Access Improvement Act

H.R. 447: Affordable and Safe Prescription Drug Importation Act - Provisions related to importation H.R. 478: Safe and Affordable Drugs from Canada Act of 2019 - Provisions related to importation H.R. 965: Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act of 2019 - Provisions related to Risk Evaluation and Mitigation Strategies (REMS) and limited distribution systems H.R. 985: FAST Generics Act of 2019 - Provisions related to Risk Evaluation and Mitigation Strategies (REMS) and limited distribution systems H.R. 1093: Stop Price Gouging Act - Provisions related to prescription drug pricing H.R. 1478: Affordable Insulin Act of 2019 - Provisions related to importation H.R. 1506: Fair and Immediate Release (FAIR) of Generic Drugs Act - Provisions related to generic prescription drug approvals H.R. 1922: Restoring Access to Medication Act of 2019 - Provisions related to prescription drug access H.R. 2064: To amend title XI of the Social Security Act to require manufacturers of certain drugs, devices, biologicals, and medical supplies to report on product samples provided to certain health care providers, and for other purposes - Provisions related to prescription drug samples H.R. 2069: Stopping the Pharmaceutical Industry from Keeping Drugs Expensive (SPIKE) Act of 2019 - Provisions related to increases in the wholesale acquisition costs of prescription drugs H.R. 2087: Drug Price Transparency Act - Provisions related to prescription drug pricing and transparency H.R. 2113: Prescription Drug STAR Act - Provisions related to prescription drug pricing, reporting and product samples H.R. 2296: FAIR Drug Pricing Act of 2019 / More Efficient Tools to Realize Information for Consumers Act - Provisions related to prescription drug pricing and transparency H.R. 2376: Prescription Pricing for the People Act of 2019 - Provisions related to prescription drug pricing transparency and pharmacy benefit managers H.R. 2569: Comprehensive Addiction Resources Emergency Act of 2019 - Provisions related to opioid crisis response funding H.R. 2732: Lessening Addiction By Enhancing Labeling Opioids Act of 2019 - Provisions related to labeling of prescription drugs H.R. 2734: Safer Prescribing of Controlled Substances Act - Provisions related to the prescribing of prescription drugs H.R. 2917: Opioid Crisis Accountability Act of 2019 - Provisions related to prescription drug marketing H.R. 3223: Pharmacy Benefit Manager Accountability Study Act of 2019 - Provisions related to prescription drug pricing transparency and pharmacy benefit managers H.R. 3327: Drug Price Transparency for Medicare Patients Act of 2019 - Provisions related to direct-to-consumer prescription drug advertising H.R. 3415: Real-Time Beneficiary Drug Cost Bill - Provisions related to drug pricing transparency H.R. 3947: Competition Prescription Act of 2019 - Provisions related to prescription drug pricing, patents, and other provisions H.R. 4010: Emergency Access to Insulin Act of 2019 - Provisions related to prescription drug access programs H.R. 4106: Responsibility in Drug Advertising Act of 2019 - Provisions related to direct-to-consumer prescription drug advertising H.R. 4158: CURE High Drug Prices Act - Provisions related to prescription drug pricing and transparency H.R. 4439: Creating Hope Reauthorization Act - Provisions related to rare disease priority review vouchers H.R. 4538: Closing Loopholes for Orphan Drugs Act - Provisions related to 340B prescription drug exclusions H.R. 4633: Investing in Safety and Innovation Act of 2019 - Provisions related to FDA programs reauthorization H.R. 4640: Affordable Pricing for Taxpayer-Funded Prescription Drugs Act of 2019 - Provisions related to prescription drug pricing and negotiation H.R. 4667: Biomedical Innovation Expansion Act of 2019 - Provisions related to NIH programs reauthorization H.R. 4710: Pharmaceutical Independence Long-Term Readiness Reform Act - Provisions related to the supply chain H.R. 4711: No Tax Breaks for Drug Ads Act - Provisions related to direct-to-consumer prescription drug advertising H.R. 4812: Ensuring Compliance Against Drug Diversion Act of 2019 - Provisions related to registrations under the Controlled Substances Act H.R. 4814: Suspicious Order Identification Act of 2019 - Provisions related to reporting on distribution of controlled substances H.R. 4906: Insulin Price Reduction Act - Provisions related to prescription drug pricing and transparency H.R. 4963: Stop the Importation and Manufacturing of Synthetic Analogues Act of 2019 - Provisions related to synthetic analogues H.R. 5031: Medical Innovation Act of 2019 - Provisions related to prescription drug manufacturer taxation and supplemental fees H.R. 5198: Patients' Right to Know Their Medication Act of 2019 - Provisions related to prescription drug labeling H.R. 5239: Prescription Drug Price Reporting Act - Provisions related to prescription drug pricing transparency H.R. 5304: PBM Transparency in Prescription Drug Costs Act - Provisions related to prescription drug pricing transparency H.R. 5381: International Pharmaceutical Transparency Act of 2019 - Provisions related to prescription drug labeling H.R. 5382: To create a mechanism whereby insulin manufacturers may sell directly to consumers at current net prices - Provisions related to prescription drug pricing H.R. 5442: To amend title XXVII of the Public Health Service Act and title XVIII of the Social Security Act to require pharmacies to disclose any differential between the cost of a prescription drug based on whether certain individuals use prescription drug coverage to acquire such drug, and for other purposes - Provisions related to prescription drug pricing and transparency H.R. 5497: Conditional Approval Act - Provisions related to approval pathway S. 61: Safe and Affordable Drugs from Canada Act of 2019 - Provisions related to importation S. 73: End Taxpayer Subsidies for Drug Ads Act - Provisions related to direct-to-consumer prescription drug advertising S. 97: Affordable and Safe Prescription Drug Importation Act - Provisions related to importation S. 340: Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act of 2019 - Provisions related to Risk Evaluation and Mitigation Strategies (REMS) and limited distribution systems S. 378: Stop Price Gouging Act - Provisions related to prescription drug pricing S. 474: Stopping the Pharmaceutical Industry from Keeping Drugs Expensive (SPIKE) Act of 2019 - Provisions related to increases in the wholesale acquisition costs of prescription drugs S. 637: Combatting Unreasonable Rises and Excessively (CURE) High Drug Prices Act - Provisions related to prescription drug pricing and transparency S. 657: Drug Price Transparency Act - Provisions related to prescription drug pricing transparency and commercial market rebates S. 660: Efficiency and Transparency in Petitions Act - Provisions related to the FDA citizen petition process S. 1140: Protecting Access to Biosimilars Act of 2019 - Provisions related to biological products S. 1227: Prescription Pricing for the People Act of 2019 - Provisions related to prescription drug pricing transparency and pharmacy benefit managers S. 1250: American Cures Act - Provisions related to pharmaceutical research and development S. 1391: FAIR Drug Pricing Act of 2019 - Provisions related to prescription drug pricing and transparency S. 1437: Drug-price Transparency in Communications (DTC) Act - Provisions related to direct-to-consumer prescription drug advertising S. 1532: Pharmacy Benefit Manager Accountability Study Act of 2019 - Provisions related to prescription drug pricing transparency and pharmacy benefit managers S. 2004: Emergency Access to Insulin Act of 2019 - Provisions related to prescription drug pricing S. 2103: Affordable Insulin Approvals Now Act - Provisions related to FDA prescription drug approvals S. 2161: Reciprocity Ensures Streamlined Use of Lifesaving Treatments Act of 2019 - Provisions related to reciprocity S. 2199: Insulin Price Reduction Act - Provisions related to prescription drug pricing and transparency S. 2723: Mitigating Emergency Drug Shortages Act - Provisions related to prescription drug pricing transparency and other provisions S. 2897: Patient-Centered Outcomes Research Institute Reauthorization Act - Provisions related to PCORI reauthorization Transparency policy issues Drug cost and pricing policy issues Drug importation and counterfeiting policy issues HHS Safe Importation Action Plan Prescription drug take back and secure disposal policy issues Policy issues related to prescription drug abuse and opioids Expanded access policy issues Generic drug approval process policy issues High deductible health plans/HSA policy issues Sharing of truthful and non-misleading information about medicines with healthcare professionals and payors Risk Evaluation and Mitigation Strategy (REMS) policy issues FDA modernization policy issues PDUFA implementation policy issues 340B drug discount program policy issues Bipartisan Budget Act of 2018 (Public Law 115-123) - Part D provisions Patient assistance program policy issues Foreign manufacturing policy issues Biosimilar approval and reimbursement policy issues Drug compounding policy issues including federal oversight of compounded drugs Cancer drug vial size policy issues TRICARE pharmacy pilot program Drug shortages policy issues Request for Information: HHS Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs (RIN 0991-ZA49) Proposed Rule; Importation of Prescription Drugs (RIN 0910-AI45)

OPM Reorganization H.R.2003 - 116th Congress (2019-2020) Ensuring FEHBP Coverage During Shutdowns Act Sponsor: Rep. Cummings, Elijah E. [D-MD-7] H.R.2004 - 116th Congress (2019-2020) Ensuring FEDVIP and FLTCIP Coverage During Shutdowns Act Sponsor: Rep. Cummings, Elijah E. [D-MD-7] S. 2004 - 116th Congress (2019-2020) Ensuring FEDVIP and FLTCIP Coverage During Shutdowns Act Rep. Elijah Cummings (D-MD-07) S.973 - 116th Congress (2019-2020) Ensuring FEDVIP and FLTCIP Coverage During Shutdowns Act Sponsor: Sen. Smith, Tina [D-MN] (Introduced 04/01/2019) S.971 - 116th Congress (2019-2020) Ensuring FEHBP Coverage During Shutdowns Act Sponsor: Sen. Smith, Tina [D-MN] (Introduced 04/01/2019)

Client expense: $1,840,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Labor, Dept of (DOL), Office of Management & Budget (OMB), SENATE, White House Office

Affordable Care Act (ACA); ACA Regulations; ACA Stabilization; Health Reform; Rural Healthcare; Risk Adjustment; State Flexibility; Opioids; Sober Homes; Marketplace Stability; Individual Market Reform; Value-based Care; Health Care Costs; Mental Health; Small Business Plans; Reinsurance; CSRs; SNPs; FEHBP Issues; 42 CFR Part 2; Transparency; Silverloading; Health IT; Interoperability; Texas lawsuit; Surprise billing, Transparency, Small Business, State Flexibility; Health Reimbursement Arrangements (HRAs)Outreach, Education, and Enrollment; Prior Authorization; All payer claims database; Negotiated rate disclosure; Consumer-facing app disclosures; Provider directories; Medicare for All; Medicare Buy-in; Maternal health; Senior's health care; Social determinants of health; Community health; Lyme disease; Cybersecurity, NBPP (Notice Benefit and Payment Parameters) H.R.1346 - 116th Congress (2019-2020) Medicare Buy-In and Health Care Stabilization Act of 2019 Sponsor: Rep. Higgins, Brian [D-NY-26] (Introduced 02/25/2019) H.R.1384 - 116th Congress (2019-2020) Medicare for All Act of 2019 Sponsor: Rep. Jayapal, Pramila [D-WA-7] (Introduced 02/27/2019) H.R.3502 - 116th Congress (2019-2020) Protecting People From Surprise Medical Bills Act Sponsor: Rep. Ruiz, Raul [D-CA-36] (Introduced 06/26/2019) Cosponsors: (48) H.R.2003 - 116th Congress (2019-2020) Ensuring FEHBP Coverage During Shutdowns Act Sponsor: Rep. Cummings, Elijah E. [D-MD-7] (Introduced 04/01/2019) H.R.2004 - 116th Congress (2019-2020) Ensuring FEDVIP and FLTCIP Coverage During Shutdowns Act Sponsor: Rep. Cummings, Elijah E. [D-MD-7] (Introduced 04/01/2019) S.973 - 116th Congress (2019-2020) Ensuring FEDVIP and FLTCIP Coverage During Shutdowns Act Sponsor: Sen. Smith, Tina [D-MN] (Introduced 04/01/2019) S.971 - 116th Congress (2019-2020) Ensuring FEHBP Coverage During Shutdowns Act Sponsor: Sen. Smith, Tina [D-MN] (Introduced 04/01/2019) H.R.1385 - 116th Congress (2019-2020) SAVE Act Sponsor: Rep. Kim, Andy [D-NJ-3] (Introduced 02/27/2019) H.R.1386 - 116th Congress (2019-2020) ENROLL Act of 2019 Sponsor: Rep. Castor, Kathy [D-FL-14] (Introduced 02/27/2019) H.R.987 - Strengthening Health Care and Lowering Prescription Drug Costs Act 116th Congress (2019-2020) Sponsor: Rep. Blunt Rochester, Lisa [D-DE-At Large] (Introduced 02/06/2019) H.R.1010 - 116th Congress (2019-2020) To provide that the rule entitled "Short-Term, Limited Duration Insurance" shall have no force or effect. Sponsor: Rep. Castor, Kathy [D-FL-14] (Introduced 02/06/2019) H.R.986 - 116th Congress (2019-2020) Protecting Americans with Preexisting Conditions Act of 2019 Sponsor: Rep. Kuster, Ann M. [D-NH-2] (Introduced 02/06/2019) H.R.1425 - 116th Congress (2019-2020) State Health Care Premium Reduction Act Sponsor: Rep. Craig, Angie [D-MN-2] (Introduced 02/28/2019) H.R.1143 - 116th Congress (2019-2020) Educating Consumers on the Risks of Short-Term Plans Act of 2019 Sponsor: Rep. Eshoo, Anna G. [D-CA-18] (Introduced 02/11/2019) H.R.1520 - 116th Congress (2019-2020) Purple Book Continuity Act of 2019 Sponsor: Rep. Eshoo, Anna G. [D-CA-18] (Introduced 03/05/2019) S.1895 - 116th Congress (2019-2020) Lower Health Care Costs Act Sponsor: Sen. Alexander, Lamar [R-TN] (Introduced 06/19/2019) H.R.1046 - 116th Congress (2019-2020) Medicare Negotiation and Competitive Licensing Act of 2019 Sponsor: Rep. Doggett, Lloyd [D-TX-35] H.R.1897 - 116th Congress (2019-2020) MOMMA's Act Sponsor: Rep. Kelly, Robin L. [D-IL-2] (Introduced 03/27/2019) H.R.1551 - 116th Congress (2019-2020) Quality Care for Moms and Babies Act Sponsor: Rep. Engel, Eliot L. [D-NY-16] (Introduced 03/06/2019 H.R.2902 - 116th Congress (2019-2020) Maternal CARE Act Sponsor: Rep. Adams, Alma S. [D-NC-12] H.R.2602 - 116th Congress (2019-2020) Healthy MOMMIES Act Sponsor: Rep. Pressley, Ayanna [D-MA-7] H.R.3630 - 116th Congress (2019-2020) No Surprises Act Sponsor: Rep. Pallone, Frank, Jr. [D-NJ-6] H.R.4378 - 116th Congress (2019-2020) Continuing Appropriations Act, 2020, and Health Extenders Act of 2019 Sponsor: Rep. Lowey, Nita M. [D-NY-17] H.R.2328 - 116th Congress (2019-2020) Community Health Investment, Modernization, and Excellence Act of 2019 Sponsor: Rep. O'Halleran, Tom [D-AZ-1] H.R.3439 - 116th Congress (2019-2020) PATIENT Act Sponsor: Rep. Beyer, Donald S., Jr. [D-VA-8] H.R.3107 - 116th Congress (2019-2020) Improving Seniors' Timely Access to Care Act of 2019 Sponsor: Rep. DelBene, Suzan K. [D-WA-1] H.R.4004 - 116th Congress (2019-2020) Social Determinants Accelerator Act of 2019 Sponsor: Rep. Bustos, Cheri [D-IL-17] H.R.2279 - 116th Congress (2019-2020) Safe Step Act Sponsor: Rep. Ruiz, Raul [D-CA-36] H.R.360 - 116th Congress (2019-2020) Cyber Sense Act of 2019 Sponsor: Rep. Latta, Robert E. [R-OH-5] S.1895 - 116th Congress (2019-2020) Lower Health Care Costs Act Sponsor: Sen. Alexander, Lamar [R-TN] S. 2897 - 116th Congress (2019-2020) Patient-Centered Outcomes Research Institute Reauthorization Act Sponsor: Sen. Mark Warner (D-VA) S. 2546 - 116th Congress (2019-2020) Safe Step Act Sen. Lisa Murkowski (R-AK) S. 2004 - 116th Congress (2019-2020) Ensuring FEDVIP and FLTCIP Coverage During Shutdowns Act Rep. Elijah Cummings (D-MD-07) H.R. 2774 - 116th Congress (2019-2020) Primary Care Patient Protection Act of 2019 Rep. Brad Schneider (D-IL-10)

S. 1895 - Lower Health Care Costs Act H.R. 2668 - Special Diabetes Program Reauthorization Act of 2019 H.R. 2680 - Special Diabetes Program for Indians Reauthorization Act of 2019 H.R. 2328 - Reauthorizing and Extending Americas Community Health Act (REACH Act) H.R. 965 - CREATES Act of 2019 S. 2543 - The Prescription Drug Pricing Reduction Act of 2019 S. 2199, H.R. 4906 - Insulin Price Reduction Act S. 2004, H.R. 4010 -- Emergency Access to Insulin Act of 2019 H.R. 3 - Lower Drug Costs Now Act of 2019 S. 2855 - Insulin Affordability Data Collection Act H.R. 19, S. 3129 - Lower Costs, More Cures Act of 2019 Issues and legislation related to drug pricing, specifically as it relates to insulin Issues and legislation related to providing flexibility in the split of a deductible between devices and prescription drugs Issues related to the importance of preserving health insurance protections for individuals with pre-existing conditions. H.R. 5254 - Diabetic Vision Loss and Blindness Prevention Act of 2019

Client expense: $120,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

H.R. 938, Bringing Low-cost Options and Competition while Keeping Incentives for New Generics (BLOCKING) Act of 2019, regarding all bio-pharmaceutical related provisions. H.R. 985, Fair Access for Safe and Timely (FAST) Generics Act of 2019, regarding all bio-pharmaceutical related provisions. H.R. 986, Protecting American with Preexisting Conditions Act of 2019, regarding all bio-pharmaceutical related provisions. H.R. 987, Marketing and Outreach Restoration to Empower Health Education Act of 2019, regarding all bio-pharmaceutical related provisions. H.R. 1010, Short-Term, Limited Duration Insurance (STLDI), regarding all bio-pharmaceutical related provisions. H.R. 1323, Rural Hospital Frontier Fairness Act, regarding all bio-pharmaceutical related provisions. H.R. 1385, State Allowance for a Variety of Exchanges (SAVE) Act, regarding all bio-pharmaceutical related provisions. H.R. 1386, Expanded Navigators Resources for Outreach, Learning, and Longevity (ENROLL) Act, regarding all bio-pharmaceutical related provisions. H.R. 1409, Transparency in All Health Care Pricing Act, regarding all bio-pharmaceutical related provisions. H.R. 1425, State Health Care Premium Reduction Act, regarding all bio-pharmaceutical related provisions. H.R. 1478, Insulin importation, regarding all bio-pharmaceutical related provisions. H.R. 1503, Orange Book Transparency Act, regarding all bio-pharmaceutical related provisions. H.R. 1506, Fair and Immediate Release (FAIR) of Generics Act, regarding all bio-pharmaceutical related provisions. H.R. 1520, Purple Book Continuity Act, regarding all bio-pharmaceutical related provisions. H.R. 2011, Protecting Access to Biosimilars Act of 2019, regarding all bio-pharmaceutical related provisions. H.R. 2038, State-based , Market-Oriented, Prescription Drug Negotiations Act of 2019, regarding all bio-pharmaceutical related provisions. H.R. 2064, Product Sample reporting, regarding all bio-pharmaceutical related provisions. S. 61, Safe and Affordable Drugs from Canada Act, regarding all bio-pharmaceutical related provisions. S. 97, Affordable and Safe Drug Importation Act, regarding all bio-pharmaceutical related provisions. S. 102, Prescription Drug Price Relief Act, regarding all bio-pharmaceutical related provisions. S. 344/H.R. 990, Hatch-Waxman Integrity Act, regarding all bio-pharmaceutical related provisions. S. 366/H.R. 1188, FLAT Prices Act- Reduced exclusivity period for certain price hikes, regarding all bio-pharmaceutical related provisions. S. 418, FDA Accountability for Public Safety Act, regarding all bio-pharmaceutical related provisions. S. 419, Protecting Americans from Dangerous Opioids Act, regarding all bio-pharmaceutical related provisions. S. 637, CURE High Drug Prices Act, regarding all bio-pharmaceutical related provisions. S. 657, Drug Price Transparency Act, regarding all bio-pharmaceutical related provisions. S. 658, Accelerated Drug Approval for Prescription Therapies Act, regarding all bio-pharmaceutical related provisions. S. 659, Biologic Patent Transparency Act, regarding all bio-pharmaceutical related provisions. S. 660, Transparency in Petitions Act, regarding all bio-pharmaceutical related provisions. S. 709, Establishes public dashboard for price and utilization of drugs purchased by federal programs, regarding all bio-pharmaceutical related provisions. S. 741 /H.R. 1730, Cancer Drug Parity Act, regarding all bio-pharmaceutical related provisions. S. 844, Short Competition Act, regarding all bio-pharmaceutical related provisions. S. 977, Transparent Drug Pricing Act of 2019, regarding all bio-pharmaceutical related provisions. S. 989, STEER Act, regarding all bio-pharmaceutical related provisions. S. 1140, A bill to amend the Public Health Service Act with respect to the treatment under section 351(k)(7) of such Act (relating to exclusivity for reference products) of certain products deemed to have a biological product license pursuant to section 7002 of the Biologics Price Competition and Innovation Act of 2009, regarding all bio-pharmaceutical related provisions. S.1169, FDA citizen petition, regarding all bio-pharmaceutical related provisions. S. 1209, A bill to amend the Federal Food, Drug, and Cosmetic Act with respect to approval of abbreviated new drug applications, regarding all bio-pharmaceutical related provisions. H.R. 2115, Public Disclosure of Drug Discounts Act, regarding all bio-pharmaceutical related provisions H.R.2296/S.1391, FAIR Drug Pricing Act, regarding all bio-pharmaceutical related provisions H.R.2700, Lowering Prescription Drug Costs and Extending Community Health Centers and other Health Priorities Act, regarding all bio-pharmaceutical related provisions H.R. 3223, Pharmacy Benefit Manager Accountability Study Act, regarding all bio-pharmaceutical related provisions S. 1361/H.R.2584, Preventive Health Savings Act, regarding all bio-pharmaceutical related provisions S. 1437, DTC Act, regarding all bio-pharmaceutical related provisions S.1532, Pharmacy Benefit Managers Accountability Study Act, regarding all bio-pharmaceutical related provisions S.1636, Ensuring Innovation Act, regarding all bio-pharmaceutical related provisions S. 1664, Prescription Drug Price Reporting Act, regarding all bio-pharmaceutical related provisions S. 1801, Affordable Medications Act, regarding all bio-pharmaceutical related provisions S. 1895, Lowering Health Costs Act, regarding all bio-pharmaceutical related provisions S. 1897, a bill to establish a process for updating the labeling of certain drugs with outdated labeling, regarding all bio-pharmaceutical related provisions S. 1897/H.R. 3523, End Price Gouging for Medications Act, regarding all bio-pharmaceutical related provisions S. 2004, Emergency Access to Insulin Act, regarding all bio-pharmaceutical related provisions H.R. 2279/S. 2546, Safe Step Act of 2019, regarding all bio-pharmaceutical related provisions

S. 192 - Community and Public Health Programs Extension Act S. 1895 - Lower Health Care Costs Act H.R. 2668 - Special Diabetes Program Reauthorization Act of 2019 H.R. 2680 - Special Diabetes Program for Indians Reauthorization Act of 2019 H.R. 965 - CREATES Act of 2019 Issues related to the proposed, Department of Health and Human Services (HHS), changes to the Anti-Kickback statutes safe harbors. Issues and legislation related to drug pricing, specifically as it relates to Insulin. S. 2004 -- Emergency Access to Insulin Act of 2019 Issues related to the importance of preserving health insurance protections for individuals with pre-existing conditions.

Client expense: $620,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

HR 1046, S 377-Medicare Negotiation and Competitive Licensing Act, S 1987-End Price Gouging for Medications act, HR 3199-TERM Act, S 1895-Lower Health Care Costs Act, S 1209-(REMEDY act), S 1416-Affordable Prescriptions for Patients Act, HR 2374, S 1224-Stop STALLING Act, HR 3379-PRICED Act, HR 2296, S 1391-(FAIR Drug Pricing Act), drug pricing, HR 2296-METRIC Act, S 2004-Emergency Access to Insulin Act, S 2387-We protect American Investments in Drugs Act (We PAID Act), S 2199-Insulin Price Reduction Act, S 977-Transparent Drug Prices Act, S 378-Stop Price Gouging Act, S 340-CREATES Act, HR 3- Patient Advocacy Transparency Act,

Client expense: $70,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE, Securities & Exchange Commission (SEC), U.S. Trade Representative (USTR)

H.R. 938, Bringing Low-cost Options and Competition while Keeping Incentives for New Generics (BLOCKING) Act of 2019, regarding all bio-pharmaceutical related provisions. H.R. 985, Fair Access for Safe and Timely (FAST) Generics Act of 2019, regarding all bio-pharmaceutical related provisions. H.R. 986, Protecting American with Preexisting Conditions Act of 2019, regarding all bio-pharmaceutical related provisions. H.R. 987, Marketing and Outreach Restoration to Empower Health Education Act of 2019, regarding all bio-pharmaceutical related provisions. H.R. 1010, Short-Term, Limited Duration Insurance (STLDI), regarding all bio-pharmaceutical related provisions. H.R. 1323, Rural Hospital Frontier Fairness Act, regarding all bio-pharmaceutical related provisions. H.R. 1385, State Allowance for a Variety of Exchanges (SAVE) Act, regarding all bio-pharmaceutical related provisions. H.R. 1386, Expanded Navigators Resources for Outreach, Learning, and Longevity (ENROLL) Act, regarding all bio-pharmaceutical related provisions. H.R. 1409, Transparency in All Health Care Pricing Act, regarding all bio-pharmaceutical related provisions. H.R. 1425, State Health Care Premium Reduction Act, regarding all bio-pharmaceutical related provisions. H.R. 1478, Insulin importation, regarding all bio-pharmaceutical related provisions. H.R. 1503, Orange Book Transparency Act, regarding all bio-pharmaceutical related provisions. H.R. 1506, Fair and Immediate Release (FAIR) of Generics Act, regarding all bio-pharmaceutical related provisions. H.R. 1520, Purple Book Continuity Act, regarding all bio-pharmaceutical related provisions. H.R. 2011, Protecting Access to Biosimilars Act of 2019, regarding all bio-pharmaceutical related provisions. H.R. 2038, State-based , Market-Oriented, Prescription Drug Negotiations Act of 2019, regarding all bio-pharmaceutical related provisions. H.R. 2064, Product Sample reporting, regarding all bio-pharmaceutical related provisions. S. 61, Safe and Affordable Drugs from Canada Act, regarding all bio-pharmaceutical related provisions. S. 97, Affordable and Safe Drug Importation Act, regarding all bio-pharmaceutical related provisions. S. 102, Prescription Drug Price Relief Act, regarding all bio-pharmaceutical related provisions. S. 344/H.R. 990, Hatch-Waxman Integrity Act, regarding all bio-pharmaceutical related provisions. S. 366/H.R. 1188, FLAT Prices Act- Reduced exclusivity period for certain price hikes, regarding all bio-pharmaceutical related provisions. S. 418, FDA Accountability for Public Safety Act, regarding all bio-pharmaceutical related provisions. S. 419, Protecting Americans from Dangerous Opioids Act, regarding all bio-pharmaceutical related provisions. S. 637, CURE High Drug Prices Act, regarding all bio-pharmaceutical related provisions. S. 657, Drug Price Transparency Act, regarding all bio-pharmaceutical related provisions. S. 658, Accelerated Drug Approval for Prescription Therapies Act, regarding all bio-pharmaceutical related provisions. S. 659, Biologic Patent Transparency Act, regarding all bio-pharmaceutical related provisions. S. 660, Transparency in Petitions Act, regarding all bio-pharmaceutical related provisions. S. 709, Establishes public dashboard for price and utilization of drugs purchased by federal programs, regarding all bio-pharmaceutical related provisions. S. 741 /H.R. 1730, Cancer Drug Parity Act, regarding all bio-pharmaceutical related provisions. S. 844, Short Competition Act, regarding all bio-pharmaceutical related provisions. S. 977, Transparent Drug Pricing Act of 2019, regarding all bio-pharmaceutical related provisions. S. 989, STEER Act, regarding all bio-pharmaceutical related provisions. S. 1140, A bill to amend the Public Health Service Act with respect to the treatment under section 351(k)(7) of such Act (relating to exclusivity for reference products) of certain products deemed to have a biological product license pursuant to section 7002 of the Biologics Price Competition and Innovation Act of 2009, regarding all bio-pharmaceutical related provisions. S.1169, FDA citizen petition, regarding all bio-pharmaceutical related provisions. S. 1209, A bill to amend the Federal Food, Drug, and Cosmetic Act with respect to approval of abbreviated new drug applications, regarding all bio-pharmaceutical related provisions. H.R. 2115, Public Disclosure of Drug Discounts Act, regarding all bio-pharmaceutical related provisions H.R.2296/S.1391, FAIR Drug Pricing Act, regarding all bio-pharmaceutical related provisions H.R.2700, Lowering Prescription Drug Costs and Extending Community Health Centers and other Health Priorities Act, regarding all bio-pharmaceutical related provisions H.R. 3223, Pharmacy Benefit Manager Accountability Study Act, regarding all bio-pharmaceutical related provisions S. 1361/H.R.2584, Preventive Health Savings Act, regarding all bio-pharmaceutical related provisions S. 1437, DTC Act, regarding all bio-pharmaceutical related provisions S.1532, Pharmacy Benefit Managers Accountability Study Act, regarding all bio-pharmaceutical related provisions S.1636, Ensuring Innovation Act, regarding all bio-pharmaceutical related provisions S. 1664, Prescription Drug Price Reporting Act, regarding all bio-pharmaceutical related provisions S. 1801, Affordable Medications Act, regarding all bio-pharmaceutical related provisions S. 1895, Lowering Health Costs Act, regarding all bio-pharmaceutical related provisions S. 1897, a bill to establish a process for updating the labeling of certain drugs with outdated labeling, regarding all bio-pharmaceutical related provisions S. 1897/H.R. 3523, End Price Gouging for Medications Act, regarding all bio-pharmaceutical related provisions S. 2004, Emergency Access to Insulin Act, regarding all bio-pharmaceutical related provisions

P.L. 111-148, Patient Protection and Affordable Care Act - provisions related to PCORI reauthorization; S. 1379, H.R. 269, Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2019 - provisions related to reauthorization of the Pandemic and All-Hazards Preparedness Act; Discussions to clarify or reform the 340B program; Discussions on value-based drug contracting; Proposals related to drug pricing, including House and Senate draft bills; H.R. 465, S. 102, The Prescription Drug Price Relief Act of 2019 - provisions related to foreign reference pricing, patents and march-in rights; S. 97, H.R. 447, The Affordable and Safe Prescription Drug Importation Act - provisions related to importation; S. 205, The Right Rebate Act of 2019 -provisions related to Medicaid drug rebates and drug classification; H.R. 938, The Bringing Low-cost Options and Competition while Keeping Incentives for New Generics Act of 2019 (the BLOCKING Act) - provisions related to 180 day generic prescription drug exclusivity; H.R. 1188, S. 366, FLAT Prices Act - provisions related to prescription drug exclusivity periods and pricing; S. 340, H.R. 965, The Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act - provisions related to Risk Evaluation and Mitigation Strategies (REMS) and limited distribution systems; H.R. 1034, Phair Pricing Act of 2019 - provisions related to Part D and manufacturer rebates; H.R. 1035; Prescription Drug Price Transparency Act - provisions related to drug pricing transparency and pharmacy benefit managers; S. 73, End Taxpayer Subsidies for Drug Ads Act - provisions related to direct-to-consumer prescription drug advertising; S. 657, Drug Price Transparency Act - provisions related to prescription drug pricing transparency and commercial market rebates; H.R. 2279, Safe Step Act - provisions related to step therapy policy; Patient Affordability Value and Efficiency Act (Not Yet Introduced) - to amend titles XI, XVIII, and XIX of the Social Security Act to promote value-based arrangements; S. 2004, Emergency Access to Insulin Act of 2019 - provisions related to biologics exclusivity; Discussions related to amending P.L. 97-414, Orphan Drug Act; H.R. 2375, S. 64, Preserve Access to Affordable Generics and Biosimilars Act - provisions related to patent settlements; H.R. 937, Right Rebate Act of 2019 - provisions related to Medicaid drug rebates and drug classification; S. 659, Biologic Patent Transparency Act - provisions related to prescription drug patent disclosures; H.R. 2069, S. 474, Stopping the Pharmaceutical Industry from Keeping drugs Expensive (SPIKE) Act of 2019 - provisions related to increases in the wholesale acquisition costs of prescription drugs; S. 977, Transparent Drug Pricing Act of 2019 - provisions related to transparency and drug pricing; S.1140, Protecting Access to Biosimilars Act of 2019 - provisions related to biological products; H.R. 2296, S. 1391, FAIR Drug Pricing Act of 2019 - provisions related to prescription drug pricing and transparency; H.R. 2455, S. 1169, Ensuring Timely Access to Generics Act of 2019 - provisions related to citizen petitions; S. 1416, Affordable Prescriptions for Patients Act of 2019 - provisions related to prescription drug patents; H.R. 3276, S. 1785, Fair AMP Act - provisions related to AMP cap, exclusion of authorized generics from AMP; Bayh-Dole march-in rights policy issues; S. 3, Keeping Health Insurance Affordable Act - provisions related to prescription drug pricing;

S. 192 - Community and Public Health Programs Extension Act S. 1895 - Lower Health Care Costs Act H.R. 2668 - Special Diabetes Program Reauthorization Act of 2019 H.R. 2680 - Special Diabetes Program for Indians Reauthorization Act of 2019 H.R. 965 - CREATES Act of 2019 Issues related to the proposed, Department of Health and Human Services (HHS), changes to the Anti-Kickback statutes safe harbors. Issues and legislation related to drug pricing, specifically as it relates to Insulin. S. 2004 -- Emergency Access to Insulin Act of 2019 S. 1948 -- Chronic Disease Management Act of 2019 Issues in the House of Representatives related to amending the Internal Revenue Code, with respect to health savings accounts (HSAs), to allow the high deductible health plans required for an HSA to provide care for chronic conditions with no deductible. Issues related to the importance of preserving health insurance protections for individuals with pre-existing conditions.

Client expense: $190,000 · Firm income: Not reported

H.R. 938, Bringing Low-cost Options and Competition while Keeping Incentives for New Generics (BLOCKING) Act of 2019, regarding all bio-pharmaceutical related provisions. H.R. 985, Fair Access for Safe and Timely (FAST) Generics Act of 2019, regarding all bio-pharmaceutical related provisions. H.R. 986, Protecting American with Preexisting Conditions Act of 2019, regarding all bio-pharmaceutical related provisions. H.R. 987, Marketing and Outreach Restoration to Empower Health Education Act of 2019, regarding all bio-pharmaceutical related provisions. H.R. 1010, Short-Term, Limited Duration Insurance (STLDI), regarding all bio-pharmaceutical related provisions. H.R. 1323, Rural Hospital Frontier Fairness Act, regarding all bio-pharmaceutical related provisions. H.R. 1385, State Allowance for a Variety of Exchanges (SAVE) Act, regarding all bio-pharmaceutical related provisions. H.R. 1386, Expanded Navigators Resources for Outreach, Learning, and Longevity (ENROLL) Act, regarding all bio-pharmaceutical related provisions. H.R. 1409, Transparency in All Health Care Pricing Act, regarding all bio-pharmaceutical related provisions. H.R. 1425, State Health Care Premium Reduction Act, regarding all bio-pharmaceutical related provisions. H.R. 1478, Insulin importation, regarding all bio-pharmaceutical related provisions. H.R. 1503, Orange Book Transparency Act, regarding all bio-pharmaceutical related provisions. H.R. 1506, Fair and Immediate Release (FAIR) of Generics Act, regarding all bio-pharmaceutical related provisions. H.R. 1520, Purple Book Continuity Act, regarding all bio-pharmaceutical related provisions. H.R. 2011, Protecting Access to Biosimilars Act of 2019, regarding all bio-pharmaceutical related provisions. H.R. 2038, State-based , Market-Oriented, Prescription Drug Negotiations Act of 2019, regarding all bio-pharmaceutical related provisions. H.R. 2064, Product Sample reporting, regarding all bio-pharmaceutical related provisions. S. 61, Safe and Affordable Drugs from Canada Act, regarding all bio-pharmaceutical related provisions. S. 97, Affordable and Safe Drug Importation Act, regarding all bio-pharmaceutical related provisions. S. 102, Prescription Drug Price Relief Act, regarding all bio-pharmaceutical related provisions. S. 344/H.R. 990, Hatch-Waxman Integrity Act, regarding all bio-pharmaceutical related provisions. S. 366/H.R. 1188, FLAT Prices Act- Reduced exclusivity period for certain price hikes, regarding all bio-pharmaceutical related provisions. S. 418, FDA Accountability for Public Safety Act, regarding all bio-pharmaceutical related provisions. S. 419, Protecting Americans from Dangerous Opioids Act, regarding all bio-pharmaceutical related provisions. S. 637, CURE High Drug Prices Act, regarding all bio-pharmaceutical related provisions. S. 657, Drug Price Transparency Act, regarding all bio-pharmaceutical related provisions. S. 658, Accelerated Drug Approval for Prescription Therapies Act, regarding all bio-pharmaceutical related provisions. S. 659, Biologic Patent Transparency Act, regarding all bio-pharmaceutical related provisions. S. 660, Transparency in Petitions Act, regarding all bio-pharmaceutical related provisions. S. 709, Establishes public dashboard for price and utilization of drugs purchased by federal programs, regarding all bio-pharmaceutical related provisions. S. 741 /H.R. 1730, Cancer Drug Parity Act, regarding all bio-pharmaceutical related provisions. S. 844, Short Competition Act, regarding all bio-pharmaceutical related provisions. S. 977, Transparent Drug Pricing Act of 2019, regarding all bio-pharmaceutical related provisions. S. 989, STEER Act, regarding all bio-pharmaceutical related provisions. S. 1140, A bill to amend the Public Health Service Act with respect to the treatment under section 351(k)(7) of such Act (relating to exclusivity for reference products) of certain products deemed to have a biological product license pursuant to section 7002 of the Biologics Price Competition and Innovation Act of 2009, regarding all bio-pharmaceutical related provisions. S.1169, FDA citizen petition, regarding all bio-pharmaceutical related provisions. S. 1209, A bill to amend the Federal Food, Drug, and Cosmetic Act with respect to approval of abbreviated new drug applications, regarding all bio-pharmaceutical related provisions. H.R. 2115, Public Disclosure of Drug Discounts Act, regarding all bio-pharmaceutical related provisions H.R.2296/S.1391, FAIR Drug Pricing Act, regarding all bio-pharmaceutical related provisions H.R.2700, Lowering Prescription Drug Costs and Extending Community Health Centers and other Health Priorities Act, regarding all bio-pharmaceutical related provisions H.R. 3223, Pharmacy Benefit Manager Accountability Study Act, regarding all bio-pharmaceutical related provisions S. 1361/H.R.2584, Preventive Health Savings Act, regarding all bio-pharmaceutical related provisions S. 1437, DTC Act, regarding all bio-pharmaceutical related provisions S.1532, Pharmacy Benefit Managers Accountability Study Act, regarding all bio-pharmaceutical related provisions S.1636, Ensuring Innovation Act, regarding all bio-pharmaceutical related provisions S. 1664, Prescription Drug Price Reporting Act, regarding all bio-pharmaceutical related provisions S. 1801, Affordable Medications Act, regarding all bio-pharmaceutical related provisions S. 1895, Lowering Health Costs Act, regarding all bio-pharmaceutical related provisions S. 1897, a bill to establish a process for updating the labeling of certain drugs with outdated labeling, regarding all bio-pharmaceutical related provisions S. 1897/H.R. 3523, End Price Gouging for Medications Act, regarding all bio-pharmaceutical related provisions S. 2004, Emergency Access to Insulin Act, regarding all bio-pharmaceutical related provisions